HEOR is changing at a rapid pace.
Let ISPOR guide you through it.

Join a global network of more than 20,000 healthcare professionals who are improving healthcare decisions

Members enjoy:
• Admission to a global network of diverse healthcare stakeholders
• Access to healthcare’s key influencers, from payers and providers to researchers and patients
• Discounts on event registrations
• Subscriptions to all ISPOR publications
• Special awards and recognition
• Exclusive online HEOR tools and cutting-edge science
• Knowledge-sharing opportunities with ISPOR colleagues

New to the field? Explore ISPOR member perks like private career development resources, members-only education and training programs, and exclusive networking opportunities!

Take advantage of your ISPOR membership
www.ispor.org/GetInvolved
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, May 18, 2019</td>
<td></td>
</tr>
<tr>
<td>7:00AM - 7:00PM</td>
<td>REGISTRATION HELP DESK HOURS</td>
</tr>
<tr>
<td>8:00AM - 12:00PM</td>
<td>SHORT COURSE MORNING SESSION</td>
</tr>
<tr>
<td>8:00AM - 5:00PM</td>
<td>SHORT COURSE FULL DAY</td>
</tr>
<tr>
<td>1:00PM - 5:00PM</td>
<td>SHORT COURSE AFTERNOON SESSION</td>
</tr>
<tr>
<td>5:30PM - 6:30PM</td>
<td>EDUCATIONAL SYMPOSIUM</td>
</tr>
<tr>
<td>Sunday, May 19, 2019</td>
<td></td>
</tr>
<tr>
<td>7:00AM - 7:00PM</td>
<td>REGISTRATION HELP DESK HOURS</td>
</tr>
<tr>
<td>8:00AM - 10:00PM</td>
<td>EXHIBITOR MOVE-IN</td>
</tr>
<tr>
<td>8:00AM - 12:00PM</td>
<td>SHORT COURSE MORNING SESSION</td>
</tr>
<tr>
<td>12:00PM - 6:00PM</td>
<td>SPEAKER READY ROOM HOURS</td>
</tr>
<tr>
<td>1:00PM - 5:00PM</td>
<td>SHORT COURSE AFTERNOON SESSION</td>
</tr>
<tr>
<td>5:00PM - 7:00PM</td>
<td>ISPOR STUDENT RESEARCH COMPETITION</td>
</tr>
<tr>
<td>5:30PM - 6:30PM</td>
<td>EDUCATIONAL SYMPOSIUM</td>
</tr>
<tr>
<td>6:30PM - 7:30PM</td>
<td>ISPOR PRESIDENTIAL RECEPTION (BY INVITATION ONLY)</td>
</tr>
<tr>
<td>7:00PM - 8:00PM</td>
<td>ISPOR STUDENT &amp; FACULTY ICEBREAKER RECEPTION</td>
</tr>
<tr>
<td>7:30PM - 9:30PM</td>
<td>ISPOR INAUGURAL AWARDS BANQUET (PREREGISTRATION ONLY)</td>
</tr>
<tr>
<td>Monday, May 20, 2019</td>
<td></td>
</tr>
<tr>
<td>7:00AM - 6:30PM</td>
<td>REGISTRATION HELP DESK HOURS</td>
</tr>
<tr>
<td>7:00AM - 8:15AM</td>
<td>ISPOR ASIA CONSORTIUM REGIONAL UPDATE</td>
</tr>
<tr>
<td>7:15AM - 8:15AM</td>
<td>EDUCATIONAL SYMPOSIUM</td>
</tr>
<tr>
<td>8:00AM - 6:00PM</td>
<td>SPEAKER READY ROOM HOURS</td>
</tr>
<tr>
<td>8:30AM - 10:30AM</td>
<td>WELCOME &amp; FIRST PLENARY SESSION: THE DAWN OF DISRUPTION IN THE HEALTH SECTOR: WILL INNOVATIVE TECHNOLOGIES REQUIRE INNOVATIVE WAYS OF THINKING?</td>
</tr>
<tr>
<td>10:30AM - 11:00AM</td>
<td>BREAK, POSTERS &amp; EXHIBIT VIEWING</td>
</tr>
<tr>
<td>10:30AM - 11:30AM</td>
<td>ISPOR BOOTH EVENT— ENGAGE WITH THE ISPOR STUDENT NETWORK. MEET THE CHAIR: KOEN DEGELING</td>
</tr>
<tr>
<td>10:30AM - 2:00PM</td>
<td>RESEARCH POSTER PRESENTATIONS - SESSION 1</td>
</tr>
<tr>
<td>10:30AM - 7:30PM</td>
<td>POSTER &amp; EXHIBIT HALL HOURS</td>
</tr>
<tr>
<td>11:00AM - 12:00PM</td>
<td>BREAKOUT SESSION 1</td>
</tr>
<tr>
<td>11:15AM - 11:45AM</td>
<td>EXHIBITOR HEOR THEATER</td>
</tr>
<tr>
<td>12:00PM - 1:30PM</td>
<td>LUNCH IN THE POSTER &amp; EXHIBIT HALL</td>
</tr>
</tbody>
</table>
### Monday, May 20, 2019 continued

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00PM – 2:00PM</td>
<td>BREAK, EXHIBITS &amp; RESEARCH POSTER PRESENTATIONS VIEWING - SESSION 1</td>
</tr>
<tr>
<td>12:15PM - 1:15PM</td>
<td>ISPOR BOOTH EVENT — NAVIGATE ISPOR'S EDUCATIONAL OFFERINGS WITH THE EDUCATION COUNCIL CHAIR: KAREN RASCATI, RPH, PHD</td>
</tr>
<tr>
<td>12:30PM - 1:30PM</td>
<td>EDUCATIONAL SYMPOSIUM</td>
</tr>
<tr>
<td>12:30PM - 1:45PM</td>
<td>ISPOR OPEN-SOURCE MODELS SPECIAL INTEREST GROUP: LIES, DAMNED LIES, AND COST-EFFECTIVENESS</td>
</tr>
<tr>
<td>12:30PM - 1:45PM</td>
<td>ISPOR REAL-WORLD EVIDENCE TRANSPARENCY COLLABORATIVE — THE CASE FOR STUDY REGISTRATION</td>
</tr>
<tr>
<td>12:30PM - 1:45PM</td>
<td>ISPOR ASIA CONSORTIUM-DRUG PRICING</td>
</tr>
<tr>
<td>12:30PM - 1:45PM</td>
<td>ISPOR ONCOLOGY SPECIAL INTEREST GROUP: IMPROVING THE AVAILABILITY AND QUALITY OF UTILITY ESTIMATES FOR THE POST-PROGRESSION PERIOD IN ONCOLOGY MODELS: RECOMMENDATIONS BASED ON A SYSTEMATIC REVIEW</td>
</tr>
<tr>
<td>12:30PM - 1:45PM</td>
<td>ISPOR HEALTH PREFERENCE METHODS SPECIAL INTEREST GROUP: FRONTIERS IN HEALTH PREFERENCE RESEARCH</td>
</tr>
<tr>
<td>12:30PM - 1:45PM</td>
<td>ISPOR LATIN AMERICA CONSORTIUM REGIONAL UPDATE</td>
</tr>
<tr>
<td>1:00PM - 2:00PM</td>
<td>POSTER AUTHOR DISCUSSION HOUR - SESSION 1</td>
</tr>
<tr>
<td>2:00PM - 3:00PM</td>
<td>ISPOR BOOTH EVENT — MAKE THE MOST OF YOUR ISPOR EXPERIENCE: UPDATE YOUR PROFILE AND ENTER TO WIN A MINI IPAD</td>
</tr>
<tr>
<td>2:15PM - 3:15PM</td>
<td>SPOTLIGHT SESSION — BACK TO THE FUTURE IN VALUE IN HEALTH</td>
</tr>
<tr>
<td>2:15PM - 3:15PM</td>
<td>SPOTLIGHT SESSION — BEYOND ONE SIZE FITS ALL: THE IMPORTANCE OF HETEROGENEITY IN PREFERENCE RESEARCH</td>
</tr>
<tr>
<td>2:15PM - 3:15PM</td>
<td>SPOTLIGHT SESSION — GLOBAL DEVELOPMENTS IN ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN HEALTHCARE</td>
</tr>
<tr>
<td>2:30PM - 3:00PM</td>
<td>EXHIBITOR HEOR THEATER</td>
</tr>
<tr>
<td>3:15PM - 3:45PM</td>
<td>BREAK, EXHIBITS &amp; RESEARCH POSTER PRESENTATIONS VIEWING - SESSION 2</td>
</tr>
<tr>
<td>3:15PM - 4:15PM</td>
<td>ISPOR BOOTH EVENT— GLOBAL NETWORKS: EXPLORE THE BENEFITS OF TRANSITIONING FROM CONFERENCE REGISTRANT TO MEMBER</td>
</tr>
<tr>
<td>3:30PM - 4:30PM</td>
<td>ISPOR STUDENT RESEARCH SPOTLIGHT</td>
</tr>
<tr>
<td>3:30PM - 7:00PM</td>
<td>RESEARCH POSTER PRESENTATIONS - SESSION 2</td>
</tr>
<tr>
<td>3:45PM - 4:45PM</td>
<td>BREAKOUT SESSION 2</td>
</tr>
<tr>
<td>4:00PM - 4:30PM</td>
<td>EXHIBITOR HEOR THEATER</td>
</tr>
<tr>
<td>5:00PM - 6:00PM</td>
<td>BREAKOUT SESSION 3</td>
</tr>
<tr>
<td>5:00PM - 6:00PM</td>
<td>ISPOR NEW PROFESSIONAL EVENT — CAREER ADVICE ACROSS THE GLOBE</td>
</tr>
<tr>
<td>6:00PM - 7:00PM</td>
<td>POSTER AUTHOR DISCUSSION HOUR - SESSION 2</td>
</tr>
<tr>
<td>6:00PM - 7:00PM</td>
<td>ISPOR BOOTH EVENT — VALUE IN HEALTH'S 20TH ANNIVERSARY CELEBRATION</td>
</tr>
<tr>
<td>6:00PM - 7:30PM</td>
<td>WELCOME RECEPTION IN THE EXHIBIT HALL</td>
</tr>
<tr>
<td>6:00PM - 9:00PM</td>
<td>“DINE-AROUND” WITH WOMEN IN HEOR (BY RESERVATION)</td>
</tr>
<tr>
<td>7:30PM - 9:00PM</td>
<td>ISPOR GLOBAL NETWORKS RECEPTION</td>
</tr>
</tbody>
</table>
**Tuesday, May 21, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00AM - 6:30PM</td>
<td>REGISTRATION HELP DESK HOURS</td>
</tr>
<tr>
<td>7:15AM - 8:15AM</td>
<td>EDUCATIONAL SYMPOSIUM</td>
</tr>
<tr>
<td>8:00AM - 6:00PM</td>
<td>SPEAKER READY ROOM HOURS</td>
</tr>
<tr>
<td>8:30AM - 10:30AM</td>
<td>WELCOME &amp; SECOND PLENARY SESSION: MEDICAL DEVICE INNOVATION AND REGULATION: TURBOCHARGED FOR SUCCESS?</td>
</tr>
<tr>
<td>10:30AM - 11:00AM</td>
<td>BREAK, POSTERS AND EXHIBIT VIEWING</td>
</tr>
<tr>
<td>10:30AM - 11:30AM</td>
<td>ISPOR BOOTH EVENT— ISPOR MEMBERSHIP: HOW TO GET MORE INVOLVED</td>
</tr>
<tr>
<td>10:30AM - 2:00PM</td>
<td>RESEARCH POSTER PRESENTATIONS - SESSION 3</td>
</tr>
<tr>
<td>10:30AM - 7:30PM</td>
<td>POSTER &amp; EXHIBIT HALL HOURS</td>
</tr>
<tr>
<td>11:00AM - 12:00PM</td>
<td>BREAKOUT SESSION 4</td>
</tr>
<tr>
<td>11:15AM - 11:45AM</td>
<td>EXHIBITOR HEOR THEATER</td>
</tr>
<tr>
<td>12:00PM – 1:30PM</td>
<td>LUNCH IN THE POSTER &amp; EXHIBIT HALL</td>
</tr>
<tr>
<td>12:00PM - 2:00PM</td>
<td>EXHIBITS &amp; RESEARCH POSTER PRESENTATIONS VIEWING – SESSION 3</td>
</tr>
<tr>
<td>12:30PM - 1:30PM</td>
<td>EDUCATIONAL SYMPOSIUM</td>
</tr>
<tr>
<td>12:30PM - 1:45PM</td>
<td>ISPOR POLAND AND ISPOR UKRAINE CHAPTERS: NEW VALUE AND COVERAGE FOR INNOVATIVE MEDICINES IN CEE</td>
</tr>
<tr>
<td>12:30PM - 1:45PM</td>
<td>ISPOR PERSONALIZED PRECISION MEDICINE SPECIAL INTEREST GROUP: LEVERAGING REAL WORLD EVIDENCE TO ADDRESS UNCERTAINTY FOR TRANSFORMATIVE AND CURATIVE THERAPIES</td>
</tr>
<tr>
<td>12:30PM - 1:45PM</td>
<td>ISPOR REAL-WORLD EVIDENCE SPECIAL INTEREST GROUP</td>
</tr>
<tr>
<td>12:30PM - 1:45PM</td>
<td>ISPOR DIGITAL HEALTH SPECIAL INTEREST GROUP</td>
</tr>
<tr>
<td>12:30PM - 1:45PM</td>
<td>ISPOR PATIENT CENTERED SPECIAL INTEREST GROUP: HOW CAN HEALTH ECONOMICS AND OUTCOMES RESEARCHERS BE TORCHBEARERS FOR PATIENT ENGAGEMENT?</td>
</tr>
<tr>
<td>12:30PM - 1:45PM</td>
<td>ISPOR MEDICATION ADHERENCE AND PERSISTENCE SPECIAL INTEREST GROUP</td>
</tr>
<tr>
<td>1:00PM - 2:00PM</td>
<td>POSTER AUTHOR DISCUSSION HOUR - SESSION 3</td>
</tr>
<tr>
<td>1:00PM - 2:00PM</td>
<td>ISPOR GENERAL BUSINESS MEETING</td>
</tr>
<tr>
<td>2:15PM - 3:15PM</td>
<td>BREAKOUT SESSION 5</td>
</tr>
<tr>
<td>2:30PM - 3:00PM</td>
<td>EXHIBITOR HEOR THEATER</td>
</tr>
<tr>
<td>3:15PM - 3:45PM</td>
<td>BREAK &amp; EXHIBITS VIEWING</td>
</tr>
<tr>
<td>3:30PM - 4:30PM</td>
<td>ISPOR BOOTH EVENT— TIPS AND ADVICE FOR NEW HEOR PROFESSIONALS: MEET THE CHAIR ELISABETH OEHRLEIN</td>
</tr>
<tr>
<td>3:30PM - 7:00PM</td>
<td>RESEARCH POSTER PRESENTATIONS - SESSION 4</td>
</tr>
<tr>
<td>3:45PM - 4:45PM</td>
<td>BREAKOUT SESSION 6</td>
</tr>
<tr>
<td>4:00PM - 4:30PM</td>
<td>EXHIBITOR HEOR THEATER</td>
</tr>
</tbody>
</table>
**Tuesday, May 21, 2019 continued**

- **5:00PM - 6:00PM** BREAKOUT SESSION 7
- **5:00PM – 6:15PM** ISPOR WOMEN IN HEOR INITIATIVE: MENTORS AND THOUGHT LEADERSHIP: RELATIONSHIP BUILDING FOR CAREER SUCCESS
- **6:00PM - 7:00PM** POSTER AUTHOR DISCUSSION HOUR - SESSION 4
- **6:00PM - 7:30PM** NETWORKING RECEPTION IN THE EXHIBIT HALL
- **6:30PM – 7:30PM** ISPOR BOOTH EVENT — WOMEN IN HEOR NETWORKING RECEPTION

**Wednesday, May 22, 2019**

- **7:00AM - 8:15AM** ISPOR HEALTH PREFERENCE METHODS SPECIAL INTEREST GROUP
- **7:15AM - 8:15AM** EDUCATIONAL SYMPOSIUM
- **8:00AM - 2:00PM** SPEAKER READY ROOM HOURS
- **8:00AM - 3:00PM** REGISTRATION HELP DESK HOURS
- **8:30AM - 9:30AM** BREAKOUT SESSION 8
- **9:30AM - 2:00PM** POSTER & EXHIBIT HALL HOURS
- **9:30AM – 2:00PM** RESEARCH POSTER PRESENTATIONS - SESSION 5
- **9:45AM - 10:45AM** PhRMA FOUNDATION SESSION/AWARDS
- **9:45AM - 10:45AM** BREAKOUT SESSION 9
- **10:00AM - 11:00AM** ISPOR BOOTH EVENT — TAKE CONTROL OF YOUR ISPOR EXPERIENCE: UPDATE YOUR MEMBER PROFILE AND EMAIL PREFERENCES
- **10:45AM - 11:00AM** BREAK, POSTERS & EXHIBIT VIEWING
- **11:00AM – 12:30PM** WELCOME & THIRD PLENARY SESSION: IS AFFORDABILITY DRIVING A NEED TO REVOLUTIONIZE DRUG PRICING?
- **12:30PM - 1:45PM** EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION 5
- **12:30PM – 2:00PM** LUNCH IN THE POSTER & EXHIBIT HALL
- **12:45PM - 1:45PM** POSTER AUTHOR DISCUSSION HOUR - SESSION 5
- **2:00PM - 3:00PM** BREAKOUT SESSION 10

*Program subject to change. Please visit the conference website or refer to the mobile app for the most current information.*
ISPOR 2019 Conferences

**ISPOR Latin America 2019**
12-14 September 2019 | Bogotá, Colombia
*Data and Value in Healthcare: 2020 and Beyond*
Register by 30 July 2019 and save.

**ISPOR Summit 2019**
October 11, 2019 | Baltimore, MD, USA

**ISPOR Europe 2019**
2-6 November 2019 | Copenhagen, Denmark
Abstract Submission Closes: 12 June 2019
Register by 24 September 2019 and save.

Upcoming Trainings

Health Technology Assessment Training
October 2019 | Beijing, China

Looking ahead to 2020 Conferences:

**ISPOR Regional 2020**
Middle East

**ISPOR 2020**
May 16-20, 2020
Orlando, FL, USA
Abstract Submission Opens: October 1, 2019

**ISPOR Asia Pacific 2020**
12-15 September 2020
Seoul, South Korea
Abstract Submission Opens: 2 December 2019

**ISPOR Europe 2020**
14-18 November 2020
Milan, Italy
Abstract Submission Opens: 2 March 2020

For more information and to register: www.ispor.org
Conference Program Committee

ISPOR thanks the Conference Program Committee for its contributions toward developing the scientific community’s leading HEOR program.

PROGRAM COMMITTEE CO-CHAIRS

Jalpa Doshi, PhD  
University of Pennsylvania, Philadelphia, PA, USA

Brian O’Rourke, PharmD  
CADTH, Ottawa, ON, Canada

Rosanna Tarricone, PhD, MSc  
Bocconi University, Milan, Italy

RESEARCH COMMITTEE CO-CHAIRS

Patrick Hopkinson  
Bristol-Myers Squibb, Pharmaceuticals, Uxbridge, UK

Lori McLeod, PhD  
RTI Health Sciences, Research Triangle Park, NC, USA

Ebere Onukwugha, MS, PhD  
University of Maryland School of Pharmacy, Baltimore, MD, USA

Ya-Chen Tina Shih, PhD  
University of Texas, MD Anderson Cancer Center, Houston, TX, USA

ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS

Jessica Daw, PharmD, MBA  
UPMC Health Plan, Pittsburgh, PA, USA

Hemant Phatak, PhD  
EMD Serono, Inc., Rockland, MA, USA

Lotte Steuten, PhD, MSc  
Office of Health Economics, London, UK

WORKSHOP REVIEW COMMITTEE CO-CHAIRS

Bruce Gingles  
COOK Medical, Inc., Bloomington, IN, USA

K. Jack Ishak, PhD, MSc  
Evidera, Montreal, QC, Canada

Maureen Smith, MEd  
CORD and PCORI, Ottawa, ON, Canada
Thank You to Our Sponsors

Gold Level Sponsors

- Evidera
- PPD
- HealthCore
- pharmerit international

Silver Level Sponsors

- CERTARA
- TriNetX
- veradigm

Bronze Level Sponsors

- abbvie
- EVERSANA
- Johnson & Johnson
- KANTAR
- Precision Health Economics
- Precision Xtract
- prognos
- RTI Health Solutions
The healthcare sector has recently witnessed several landmark moments in the development of the next generation of medical care. While media attention has rightly focused on milestone regulatory approvals for several groundbreaking curative treatments and devices, the best is likely yet to come: over 2600 clinical trials of gene therapies are either completed or ongoing; nearly 1000 trials of regenerative medicine are in progress worldwide; and more than 7000 trials for medical devices ranging from bionic eye brain implants to spinal cord stimulators are underway. Disruption will not be limited to drugs and devices. Advances in the applications of 3-D printing as well as artificial intelligence have the potential to generate powerful new tools for disease prevention, diagnosis, and treatment. In short, innovations that have long been the stuff of science fiction may no longer be distant points on the horizon. Are we entering a “golden age” of disruptive innovation in medical care? What new challenges and opportunities will these technologies bring? How can a health sector attuned to an old way of doing things truly prepare for treatments that break the mold? This plenary session will begin with an overview of the current and future landscape followed by a discussion among leading experts. Emerging challenges and opportunities presented by disruptive technologies will be addressed from the perspective of regulators, payers, manufacturers, providers, and patients.

Keynote Speaker: Daniel Kraft, MD, Singularity University and Exponential Medicine, Stanford, CA, USA
Moderator: Clifford Goodman, PhD, The Lewin Group, Falls Church, VA, USA
Speakers: Timothy Caulfield, LL.M., University of Alberta, Edmonton, AB, Canada; Fleur Chandler, Duchenne, Twickenham, England; Rebekah E. Gee, MD, MPH, Louisiana Department of Health, Baton Rouge, LA, USA; Ron Philip, Spark Therapeutics, Inc., Philadelphia, PA, USA

The medical implants market is one of the fastest-growing in healthcare. Yet alongside this rapid growth, the industry is facing increasing calls for regulation and oversight. As the demand for innovative medical devices accelerates, how can regulators ensure the highest level of health protection without hindering research and growth in the sector? This tension emerges from the two forces shaping the medical devices market: companies that are driving innovation, eager to bring needed new advances to patients and clinicians as quickly as possible and the regulators, responsible for governing the parameters of these advances. So how will the latest legislation fare? The new EU Medical Devices Regulation ([EU] 2017/745) will come into force on May 26, 2020 and is intended to “ensure a high level of safety and health while supporting innovation.” Other regulators such as the FDA are also instituting major changes to their medical device regulations. How will these new regulations better guarantee patients’ safety and strengthen confidence on the uptake and diffusion of medical devices? This plenary will explore how our healthcare systems navigate these controversies and identify implications and opportunities for the HEOR community, including the generation of relevant real-world evidence to support better decision making as well as what further regulations are needed. Finally, the panel will consider how such systems can evolve to keep up with the rapidly-innovating world of medical devices.

Moderator: Laurie Burke, MPH, LORA Group, LLC, Royal Oak, MD, USA
Speaker: Stephanie Christopher, MA, Medical Device Innovation Consortium, Washington, DC, USA; Paul Coplan, ScD, MBA, Johnson & Johnson, New Brunswick, NJ, USA; Stephen A. Hull, MHS, Hull Associates LLC, Rockland, MA, USA; Harindra Wijeysundera, MD, PhD, CADTH, Ottawa, ON, Canada

Promoting rapid and equitable access to promising therapies in an affordable manner is a laudable goal for all health systems. However, with the explosion of high cost, disruptive, and innovative drugs—many of which are promising a cure—payers are facing a crisis of affordability. We are in an era with six-figure cancer treatments, curative and costly gene therapies, ultra-high-cost drugs for treating orphan diseases, and even expensive drugs for more common diseases. It is an exciting and promising trend for patients, clinicians, and pharmaceutical companies, and a challenging time for payers who must now look beyond cost-effectiveness to address affordability. The ISPOR 2019 Top 10 HEOR Trends report identified drug spending and pricing as the top trend. In the United States, President Trump launched his Blueprint to Lower Drug Prices in May 2018, and a recent paper from the University of Chicago reported that average total drug spending per hospital admission increased 18.5% between 2015 and 2017. Affordability of pharmaceuticals has become a truly global issue. Is it time for a revolution in how we price, fund, and manage drugs? Are there innovative approaches that can promote access, manage affordability, and still foster innovation? What can be done to significantly improve the transparency of drug prices? How do we ensure equitable access to low- and middle-income countries and disadvantaged populations?

Moderator: Colleen Flood, University of Ottawa Centre for Health Law, Policy and Ethics, Ottawa, ON, Canada
Speakers: Muna Bhanji, RPh, Merck, Philadelphia, PA, USA; Meindert Boysen, PharmD, MSc, NICE, Manchester, England; John M. O’Brien, PharmD, MPH, US Department of Health and Human Services, Washington, DC, USA; Mark Trusheim, MS, NEWDIGS and MIT, Boston, MA, USA
Your ISPOR Conference App

At your fingertips.
It’s easy to personalize and maximize your ISPOR conference experience.

Search: ISPOR

NETWORK: ISPOR2019
WI-FI PASSWORD: HEALTHCORE

Released Presentations

Looking for presentations from ISPOR 2019?

More than 85% of presentations will be available!

www.ispor.org/ISPOR2019-Released-Presentations

Presentations are available online after each session, subject to speaker approval.
Program & Schedule of Events

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday</td>
<td>May 18</td>
</tr>
<tr>
<td>Sunday</td>
<td>May 19</td>
</tr>
<tr>
<td>Monday</td>
<td>May 20</td>
</tr>
<tr>
<td>Tuesday</td>
<td>May 21</td>
</tr>
<tr>
<td>Wednesday</td>
<td>May 22</td>
</tr>
</tbody>
</table>

Pre-Conference Short Courses are training courses offered across 7 HEOR key topic areas. The skill level ranges from introductory to advanced, and continuing education credits are available. Separate registration is required.

Plenary Sessions feature thought-provoking discussions on challenging topics related to healthcare policy, the application of HEOR in healthcare decision making, or methodology.

Spotlight Sessions (SP) highlight timely topics in HEOR and promote areas of innovation of interest to the ISPOR community.

Issue Panels (IP) introduce debates with multistakeholder perspectives on new or controversial issues in HEOR.

Workshops (W) discuss new and innovative applications in the conduct and use of HEOR or the latest on real-world data, clinical-, economic-, or patient-reported outcomes, patient-preferences, and healthcare policy.

ISPOR Forums (F) are presentations or facilitated discussions on current HEOR topics by ISPOR Member Groups (ie, Chapters, Networks, Consortia, Task Forces, Special Interest Groups, and Council Working Groups). Session content includes updates on regional issues and recent scientific research. Open to all attendees.

Podium Presentations (P) sessions consist of four 15-minute outcomes research presentations on a single topic.

Poster Presentations sessions contain approximately 350 research posters per session arranged by disease, topic, or healthcare intervention with a scheduled author discussion hour.

Symposia are sponsored presentations related to ISPOR’s mission. The sponsor organization selects a subject of interest to delegates and arranges suitable speakers.
Saturday May 18

7:00AM - 6:00PM  **COAT ROOM HOURS**  *Hall H Lobby*

7:00AM - 7:00PM  **REGISTRATION HELP DESK HOURS**  *Hall H Lobby*

7:00AM - 6:00PM  **MULTI-FAITH PRAYER ROOM**  *Room 298 (2nd Floor)*

7:00AM - 6:00PM  **NURSING MOTHERS’ ROOM**  *Room 299 (2nd Floor)*

8:00AM - 5:00PM  **SHORT COURSE FULL DAY**  *(Separate Registration Required)*

- **Introduction to Health Economics and Outcomes Research**  *Room 391 (3rd Floor)*
  - **Track:** Economic Evaluation
  - **Level:** Introductory - This course is suitable for those with little or no experience with health economics.
  - **Faculty:** Lorne Basskin, PharmD, Charleston University, Charleston, WV, USA

- **Bayesian Analysis – Overview and Applications**  *Room 386 (3rd Floor)*
  - **Track:** Methodological & Statistical Research
  - **Level:** Introductory - This course is designed for those with a limited understanding of Bayesian statistical concepts or for those who want a refresher and more practical experience.
  - **Faculty:** Christopher S. Hollenbeak, PhD, The Pennsylvania State University, Hershey, PA, USA; David J. Vanness, PhD, The Pennsylvania State University, Hershey, PA, USA

8:00AM - 12:00PM  **SHORT COURSE MORNING SESSION**  *(Separate Registration Required)*

- **Introduction to the Design & Database Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources**  *Room 394 (3rd Floor)*
  - **Track:** Study Approaches
  - **Level:** Introductory
  - **Faculty:** Bradley Martin, PharmD, PhD, RPh, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Benjamin M. Craig, PhD, University of South Florida and Moffitt Cancer Center, Tampa, FL, USA

- **Introduction to Modeling Methods**  *Room 395 (3rd Floor)*
  - **Track:** Methodological & Statistical Research
  - **Level:** Introductory - This course is suitable for those with little experience with decision analysis, and is recommended as a pre-requisite to the ISPOR short courses, “Modeling: Design and Structure of a Model,” “Bayesian Analysis,” and “Advanced Decision Modeling for Health Economic Evaluations.”
  - **Faculty:** Mark S. Roberts, MD, MPP, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA

- **Introduction to Patient Reported Outcomes**  *Room 390 (3rd Floor)*
  - **Track:** Patient-Centered Research
  - **Level:** Introductory - This course is intended for those with little experience with these methodologies.
  - **Faculty:** Tara Symonds, PhD, Clinical Outcomes Solutions, Folkestone, Kent, UK; Alexandra I. Barsdorf, PhD, Clinical Outcomes Solutions, Chicago, IL, USA; Elizabeth (Nicki) Bush, MHS, Eli Lilly and Company, Indianapolis, IN, USA

- **Utility Measures**  *Room 387 (3rd Floor)*
  - **Track:** Patient-Centered Research
  - **Level:** Introductory - No prior knowledge of utilities or health-related quality of life is assumed.
  - **Faculty:** John E. Brazier, PhD, MSc, University of Sheffield, Sheffield, UK; Brendan Mulhern, MRes, Senior Research Fellow, Health Economics and Outcomes Research, University of Technology Sydney, Sydney, Australia

- **New! Tools for Reproducible Real-World Data Analysis**  *Room 392 (3rd Floor)*
  - **Track:** Real World Data & Information Systems
  - **Level:** Intermediate
  - **Faculty:** Carrie Savage Bennette, MPH, PhD, Flatiron Health, Seattle, WA, USA; Blythe Adamson, PhD, MPH, Flatiron Health, New York, NY, USA; Joshua Kraut, MS, Flatiron Health, Seattle, WA, USA

*Indicates hands-on exercises requiring the use of your personal computer.*
## Saturday May 18

### Elements of Pharmaceutical/Biotech Pricing 1 - Introduction  
**Room 393 (3rd Floor)**

**Track:** Health Policy & Regulatory  
**Level:** Introductory  
This course is designed for those with limited experience in the area of pharmaceutical pricing and covers topics within a global context.

**Faculty:**  
**Jack M. Mycka**, Medical Marketing Economics LLC (MME), Montclair, NJ, USA;  
**Renato Dellamano, PhD**, MME Europe & ValueVector (Value Added Business Strategies), Milan, Italy

### 1:00PM - 5:00PM  
**SHORT COURSE AFTERNOON SESSION (Separate Registration Required)**

#### Case Studies in Pharmaceutical/Biotech Pricing 2 – Advanced  
**Room 393 (3rd Floor)**

**Track:** Health Policy & Regulatory  
**Prerequisite:** Participation in the ISPOR short course, “Elements of Pharmaceutical/Biotech Pricing I – Introduction,” or equivalent knowledge, is required.

**Level:** Intermediate  
This course is designed for those with limited experience in the area of pharmaceutical pricing and covers topics within a global context.

**Faculty:**  
**Jack M. Mycka**, Medical Marketing Economics LLC (MME), Montclair, NJ, USA;  
**Renato Dellamano, PhD**, MME Europe & ValueVector (Value Added Business Strategies), Milan, Italy

#### Meta-Analysis and Systematic Reviews in Comparative Effectiveness Research  
**Room 395 (3rd Floor)**

**Track:** Study Approaches  
**Level:** Introductory  
This course is designed for those having little experience with meta-analysis, or as a refresher and update for those with more experience.

**Faculty:**  
**Joseph C. Cappelleri, PhD, MPH, MS**, Pfizer Inc, Groton, CT, USA;  
**Jeroen P. Jansen, PhD**, Precision Xtract, Oakland, CA, USA

#### New! Health State Utility (HSU) Recommendations for Identification and Use of HSU Data in Cost-Effectiveness Modeling  
**Room 390 (3rd Floor)**

**Track:** Patient-Centered Research  
**Level:** Intermediate  

**Faculty:**  
**Andrew Lloyd, DPhil**, Acaster Lloyd Consulting Limited, London, UK;  
**John E. Brazier, PhD, MSc**, University of Sheffield, Sheffield, UK;  
**Jonathan Karnon, PhD**, Flinders University, Adelaide, Australia

#### Modeling: Design and Structure of a Model  
**Room 392 (3rd Floor)**

**Track:** Methodological & Statistical Research  
**Prerequisite:** Participation in the ISPOR short course, “Introduction to Modeling Methods,” or equivalent knowledge, is required.

**Level:** Intermediate  
Participants should have a basic understanding of decision analysis.

**Faculty:**  
**Shelby Corman, PharmD, MS**, Pharmerit International, Bethesda, MD, USA;  
**Mark S. Roberts, MD, MPP**, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA

#### Applications in Using Large Databases  
**Room 396 (3rd Floor)**

**Track:** Study Approaches  
**Prerequisite:** Previous attendance at the ISPOR Short Course, “Introduction to Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources,” or equivalent knowledge, is recommended.

**Level:** Intermediate  
Participants must have some knowledge of administrative healthcare database analysis.

**Faculty:**  
**Joanne LaFleur, PharmD, MPH**, George E. Whalen Veterans Health Administration IDEAS Center, Salt Lake City, UT, USA;  
**Brandon K. Bellow, PharmD, MS**, Columbia University, New York, NY, USA

#### Use of Propensity Scores in Observational Studies of Treatment Effects  
**Room 394 (3rd Floor)**

**Track:** Study Approaches  
**Prerequisite:** Previous attendance at the ISPOR Short Course, “Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources,” or equivalent knowledge, is recommended.

**Level:** Intermediate  
This course is designed for those with little experience with this methodology, but have some knowledge of observational databases.

**Faculty:**  
**John D. Seeger, PharmD, DrPH**, Optum, Waltham, MA, USA;  
**Jeremy A. Rassen, ScD**, Aetion, Inc., New York, NY, USA

#### New! US Healthcare System and Its Approach to Value and Affordability™  
**Rooms 398-399 (3rd Floor)**

**Track:** Health Policy & Regulatory  
**Level:** Introductory  
This course is designed for those having limited experience in understanding the structure of the US healthcare system, including its various subsystems and how they operate.

**Faculty:**  
**James F. Murray, PhD**, Eli Lilly and Company, Carmel, IN, USA;  
**Laura T. Pizzi, PharmD, MPH, RPh**, Rutgers University, Piscataway, NJ, USA;  
**Karen Worley, PhD**, Humana, Cincinnati, OH, USA;  
**Finn Børlum Kristensen, MD, PhD**, University of Southern Denmark, Hilleroed, Denmark

---

*Indicates hands-on exercises requiring the use of your personal computer.*
Saturday May 18

Value of Information: Active Learning, Modeling Tools and Applications  
Room 387 (3rd Floor)

Track: Economic Evaluation  
Prerequisite: Participation in the ISPOR short course, “Introduction to Modeling Methods,” or equivalent knowledge, is required.  
Level: Intermediate  
Faculty: Jonathan D. Campbell, PhD, University of Colorado Denver, Denver, CO, USA; R. Brett McQueen, PhD, University of Colorado Denver, Denver, CO, USA

5:30PM - 6:30PM  
EDUCATIONAL SYMPOSIUM  
Rooms 383-385 (3rd Floor)

De-Risking Risk Sharing: Enabling Payer-Pharma Interactions and Value-Based Contracting With RWE

Sponsored by: Aetion  
Speakers: Sebastian Schneeweiss, MD, ScD, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Jeremy Rassen, ScD, Aetion, Inc., New York, NY, USA

Indicates hands-on exercises requiring the use of your personal computer.
Sunday May 19

7:00AM - 6:00PM  **COAT ROOM HOURS  Hall H Lobby**

7:00AM - 7:00PM  **REGISTRATION HELP DESK HOURS  Hall H Lobby**

7:00AM - 8:00PM  **MULTI-FaITH PRAYER ROOM  Room 298 (2nd Floor)**

7:00AM - 8:00PM  **NURSING MOTHERS’ ROOM  Room 299 (2nd Floor)**

8:00AM - 10:00PM  **EXHIBITOR MOVE-IN  Poster and Exhibit Hall, Hall H**

8:00AM - 12:00PM  **SHORT COURSE MORNING SESSION** *(Separate Registration Required)*

- **Using DICE Simulation for Health Economic Analyses  Room 392 (3rd Floor)**
  
  **Track:** Methodological & Statistical Research  
  **Level:** Introductory - This course is designed for those with some familiarity with modeling.  
  **Faculty:** J. Jaime Caro, MDCM, Evidera, Waltham, MA, USA and McGill University, Montreal, QC, Canada; Jörgen Möller, MSc, Evidera, Hammersmith, UK

- **Cost-Effectiveness Analysis Alongside Clinical Trials  Room 387 (3rd Floor)**
  
  **Track:** Economic Evaluation  
  **Level:** Introductory - Familiarity with economic evaluations will be helpful.  
  **Faculty:** Scott D. Ramsey, MD, PhD, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA; Richard J. Willke, PhD, ISPOR, Lawrenceville, NJ, USA

- **Statistical Methods in Economic Evaluations  Room 394 (3rd Floor)**
  
  **Track:** Economic Evaluation  
  **Level:** Intermediate - Participants should have basic knowledge of economic evaluations and statistics.  
  **Faculty:** Shelby Reed, PhD, RPh, Duke University, Durham, NC, USA; Brad Hammill, DrPh, MS, Duke University, Durham, NC, USA

- **Risk Sharing/Performance-Based Arrangements for Drugs and Other Medical Products  Room 395 (3rd Floor)**
  
  **Track:** Health Policy & Regulatory  
  **Prerequisite:** It will be helpful for individuals to have completed the ISPOR short course, “Elements of Pharmaceutical/Biotech Pricing,” or to be familiar with pharmaceutical pricing and the main international health systems.  
  **Level:** Intermediate  
  **Faculty:** Louis P. Garrison, PhD, University of Washington, Seattle, WA, USA; Adrian Towse, MA, MPhil, Office of Health Economics, London, UK; Josh Carlson, MPH, PhD, University of Washington, Seattle, WA, USA

- **Stated Preference Methods – Part 1  Room 390 (3rd Floor)**
  
  **Track:** Patient-Centered Research  
  **Level:** Introductory  
  **Faculty:** Brett Hauber, PhD, RTI Health Solutions, Research Triangle Park, NC, USA; Deborah Marshall, PhD, University of Calgary, Calgary, AB, Canada; John F. P. Bridges, PhD, The Ohio State University College of Medicine, Columbus, OH, USA

- **Advanced Patient-Reported Outcomes  Room 393 (3rd Floor)**
  
  **Track:** Patient-Centered Research  
  **Level:** Advanced  
  **Faculty:** Cheryl Coon, PhD, Outcometrix, Tucson, AZ, USA; Jason Lundy, PhD, Outcometrix, Tucson, AZ, USA

- **Use of Instrumental Variables in Observational Studies of Treatment Effects  Room 386 (3rd Floor)**
  
  **Track:** Study Approaches  
  **Prerequisite:** Previous attendance at the ISPOR short course, “Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources,” or equivalent knowledge, is recommended.  
  **Level:** Intermediate - This course is suitable for those with some knowledge of econometrics.  
  **Faculty:** Benjamin M. Craig, PhD, University of South Florida and Moffitt Cancer Center, Tampa, FL, USA; Bradley Martin, PharmD, PhD, RPh, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Antoine C. El Khoury, PhD, MS, Janssen Pharmaceutical, Raritan, NJ, USA

*Indicates hands-on exercises requiring the use of your personal computer.*
Sunday May 19

**Budget Impact Analysis 1 – A 6-Step Approach Room**  Room 391 (3rd Floor)

*Track:* Economic Evaluation  
*Level:* Intermediate - This course is designed for those with some experience with pharmacoeconomic analysis.  
*Faculty:* Josephine Mauskopf, PhD, RTI Health Solutions, Research Triangle Park, NC, USA; C. Daniel Mullins, PhD, University of Maryland School of Pharmacy, Baltimore, MD, USA; Stephanie R. Earnshaw, PhD, MS, RTI Health Solutions, Research Triangle Park, NC, USA

**New! Market Access & Value Assessment of Medical Devices**  Rooms 388-389 (3rd Floor)

*Track:* Health Policy & Regulatory  
*Level:* Intermediate  
*Faculty:* Stephen A. Hull, MHS, Hull Associates LLC, Rockland, MA, USA; Michael Drummond, MCom, DPhil, University of York, Heslington, York, UK; Belinda A. Mohr, PhD, W. L. Gore & Associates, Inc., Phoenix, AZ, USA; Brian W. Bresnahan, PhD, University of Washington and Harborview Medical Center, Seattle, WA, USA

**Introduction to Health Technology Assessment**  Room 396 (3rd Floor)

*Track:* Health Technology Assessment  
*Level:* Introductory - This course is suitable for those with little or no experience with HTA.  
*Faculty:* Uwe Siebert, MPH, MSc, ScD, MD, UMIT, Hall, Austria, and Massachusetts General Hospital, Boston, MA, USA

**12:00PM - 6:00PM  SPEAKER READY ROOM**  Room 277 (2nd Floor)

**1:00PM - 5:00PM SHORT COURSE AFTERNOON SESSION**  (Separate Registration Required)

**Budget Impact Analysis 2 – Applications and Design Issues Room 392 (3rd Floor)**

*Track:* Economic Evaluation  
*Prerequisite:* Participation in the ISPOR short course, “Budget Impact Analysis I: A 6-Step Approach,” or equivalent knowledge, is recommended.  
*Level:* Intermediate - This course is designed for those who have basic knowledge of budget impact analyses and desire exposure to these analyses in Excel.  
*Faculty:* Stephanie R. Earnshaw, PhD, MS, RTI Health Solutions, Research Triangle Park, NC, USA; Anita Brogan, PhD, RTI Health Solutions, Manchester, LAN, UK; Thor-Henrik Brodtkorb, PhD, RTI Health Solutions, Ljungskile, Sweden

**Stated Preference Methods – Part 2**  Room 390 (3rd Floor)

*Track:* Patient-Centered Research  
*Level:* Intermediate  
*Faculty:* Brett Hauber, PhD, RTI Health Solutions, Research Triangle Park, NC, USA; Deborah Marshall, PhD, University of Calgary, Calgary, AB, Canada; John F. P. Bridges, PhD, The Ohio State University College of Medicine, Columbus, OH, USA

**Network Meta-Analysis Room 396 (3rd Floor)**

*Track:* Study Approaches  
*Level:* Intermediate - This course requires at least a basic knowledge of meta-analysis and statistics.  
*Faculty:* Jeroen P Jansen, PhD, Precision Xtract, Oakland, CA, USA; Joseph C. Cappelleri, PhD, MPH, MS, Pfizer Inc, Groton, CT, USA

**Advanced Decision Modeling for Health Economic Evaluations Room 391 (3rd Floor)**

*Track:* Methodological & Statistical Research  
*Prerequisite:* Previous attendance at the ISPOR short course, “Modeling: Design and Structure of a Model,” or equivalent knowledge, is required.  
*Level:* Advanced - Participants should have an understanding of decision analysis.  
*Faculty:* Mark Sculpher, PhD, University of York, York, UK; Elisabeth Fenwick, PhD, MMA, Pharmerit International, Oxford, UK

**Patient-Reported Outcomes: Item Response Theory Room 393 (3rd Floor)**

*Track:* Patient-Centered Research  
*Level:* Intermediate - This course is designed for those with little to no experience with IRT.  
*Faculty:* Bryce B. Reeve, PhD, Duke University, Durham, NC, USA

Indicates hands-on exercises requiring the use of your personal computer.
Sunday May 19

Preference Data for Patient-Centric Benefit-Risk Analysis  Room 386 (3rd Floor)
Track: Patient-Centered Research
Prerequisite: Previous attendance at the ISPOR short course, “Conjoint Analysis – Theory and Methods,” or equivalent knowledge of stated-preference methods, is required.
Level: Advanced
Faculty: F. Reed Johnson, PhD, Duke Clinical Research Institute, Durham, NC, USA; Bennett Levitan, MD, PhD, Janssen Research & Development, LLC, Titusville, NJ, USA; Juan Marcos Gonzalez Sepulveda, PhD, Assistant Professor, Duke University, Durham, NC, USA

A Health Economics Approach to US Value Assessment Frameworks  Rooms 388-389 (3rd Floor)
Track: Health Technology Assessment
Level: Introductory
Faculty: Richard J. Willke, PhD, ISPOR, Lawrenceville, NJ, USA; Louis P. Garrison, PhD, University of Washington, Seattle, WA, USA; Charles E. Phelps, PhD, MBA, University of Rochester, Gualala, CA, USA

Causal Inference and Causal Diagrams in Big, Real-World Observational Data and Pragmatic Trials  Room 395 (3rd Floor)
Track: Real-World Data & Information Systems
Prerequisite: Previous attendance at the ISPOR short course, “Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources”, or equivalent knowledge, is recommended.
Level: Advanced
Faculty: Uwe Siebert, MPH, MSc, ScD, MD, UMIT, Hall, Austria, and Massachusetts General Hospital, Boston, MA, USA; Douglas E. Faries, PhD, Eli Lilly and Company, Indianapolis, IN, USA

5:00PM - 7:00PM  ISPOR FORUMS
ISPOR Student Research Competition  Rooms 278-280 (2nd Floor)
The Student Research Competition is a quiz competition featuring teams from ISPOR Student Chapters. Questions are from the ISPOR Book of Terms and ISPOR Good Research Practices for Outcomes Research. The top 3 winning teams receive a cash prize for their ISPOR Student Chapter.  Sponsored by ISPOR

5:30PM - 6:30PM  EDUCATIONAL SYMPOSIUM  Rooms 383-385 (3rd Floor)
Able to Cure, Able to Pay: Closing the Widening Gap
Sponsored by: National Pharmaceutical Council
Moderator: Robert W. Dubois, MD, PhD, National Pharmaceutical Council, Washington, DC, USA
Speakers: Alexander Billioux, MD, Louisiana Department of Health's Office of Public Health, Baton Rouge, LA, USA; Vadim Lubarsky, MBA, Novartis Services, Inc., Washington, DC, USA

6:30PM - 7:30PM  ISPOR PRESIDENTIAL RECEPTION (By invitation only)  Hilton New Orleans Riverside

7:00PM – 8:00PM  ISPOR STUDENT & FACULTY ICEBREAKER RECEPTION  Room 281-282 (2nd Floor)
All students and faculty are welcome to attend the reception where ISPOR will be distributing prizes and students, and faculty can network with their peers in a relaxed environment. The winning design for the t-shirt competition will be handed out to all students in advance.  Sponsored by Abbvie

7:30PM - 9:30PM  ISPOR INAUGURAL AWARDS BANQUET (Separate preregistration required)  Hilton New Orleans Riverside
For more than 20 years, readers have relied on *Value in Health* to deliver high-quality, scholarly articles that advance the field of health economics and outcomes research (HEOR). Each issue contains peer-reviewed, original research, and health policy articles that help healthcare leaders make evidence-based decisions that have a real-world impact on global populations and healthcare systems.

Later this year, the journal will unveil a new look for the publication—one that reflects the level of sophistication and prominence of the role HEOR is currently playing in improving healthcare decisions. Bold new look—same trusted content.

*Value in Health*... unwrapping the science of HEOR for readers around the world.
Monday  May 20

7:00AM - 6:30PM  **REGISTRATION HELP DESK HOURS**  Hall H Lobby

7:00AM - 8:00PM  **COAT ROOM HOURS**  Hall H Lobby

7:00AM - 9:30PM  **MULTI-FaITH PRAYER ROOM**  Room 298 (2nd Floor)

7:00AM - 9:30PM  **NURSING MOTHERS’ ROOM**  Room 299 (2nd Floor)

7:00AM - 8:15AM  **ISPOR ASIA CONSORTIUM REGIONAL UPDATE**  Room 292 (2nd Floor)

The ISPOR Asia Consortium is comprised of professionals interested in promoting health economics and outcomes research (HEOR) excellence to improve healthcare decision making in Asia Pacific and globally. The Asia Consortium provides a platform for information-sharing and institutional collaboration on HEOR and health policy, facilitating professional networking opportunities through scientific activities and global ISPOR initiatives. ISPOR Asia Consortium members include a diverse range of healthcare stakeholders, including payers and policymakers, regulators and assessors, clinicians and patients, researchers and industry. Currently we have over 1000 Asia Consortium members, and 31 Chapters in Asia Pacific with over 2000 Chapter members.

7:15AM - 8:15AM  **EDUCATIONAL SYMPOSIUM**  Rooms 278-282 (2nd Floor)

21st Century FDA - Exploring the Rise of Real-World Evidence

*Sponsored by: Cardinal Health*

*Moderator: Bruce A. Feinberg, DO, Cardinal Health Specialty Solutions, Dublin, OH, USA*

*Speakers: Jonathan Kish, PhD, MPH, Cardinal Health Specialty Solutions, Dublin, OH, USA; Annette Powers, PharmD, MBA, Summit, NJ, USA; Bhakti Arondekar, BPharm, BPharm, MBA, PhD, Pfizer Inc, Collegeville, PA, USA*

8:00AM - 6:00PM  **SPEAKER READY ROOM**  Room 277 (2nd Floor)

8:30AM - 10:30AM  **WELCOME & FIRST PLENARY SESSION**  New Orleans Theater, Mid-Level Entrance

*Welcome from ISPOR CEO/Executive Director*

Nancy S. Berg, ISPOR, Lawrenceville, NJ, USA

*Presidential Address*

Federico Augustovski, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina

*Conference Program Overview from Program Committee Co-Chairs*

Jalpa Doshi, PhD, University of Pennsylvania, Philadelphia, PA, USA; Brian O’Rourke, PharmD, CADTH, Ottawa, ON, Canada; Rosanna Tarricone, PhD, MSc, Bocconi University, Milan, Italy

2019 ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award

*AWARDEE: Marc L. Berger, MD, Consultant, New York, NY, USA*

**FIRST PLENARY SESSION: THE DAWN OF DISRUPTION IN THE HEALTH SECTOR: WILL INNOVATIVE TECHNOLOGIES REQUIRE INNOVATIVE WAYS OF THINKING?**

*Keynote Speaker: Daniel Kraft, MD, Singularity University and Exponential Medicine, Stanford, CA, USA*

*Moderator: Clifford Goodman, PhD, The Lewin Group, Falls Church, VA, USA*

*Speakers: Timothy Caulfield, LLM, University of Alberta, Edmonton, AB, Canada; Fleur Chandler, Duchenne, Twickenham, England; Rebekah E. Gee, MD, MPH, Louisiana Department of Health, Baton Rouge, LA, USA; Ron Philip, Spark Therapeutics, Inc., Philadelphia, PA, USA*

10:30AM - 11:00AM  **BREAK, POSTERS AND EXHIBIT VIEWING**  Poster and Exhibit Hall, Hall H

10:30AM - 11:30AM  **ISPOR BOOTH EVENT**  Poster and Exhibit Hall, Booth #407

Engage with the ISPOR Student Network: Meet the Chair – Koen Degeling.
Monday May 20

10:30AM - 2:00PM  RESEARCH POSTER PRESENTATIONS – SESSION 1  Poster and Exhibit Hall, Hall H

10:30AM - 7:30PM  POSTER AND EXHIBIT HALL HOURS  Poster and Exhibit Hall, Hall H

11:00AM - 12:00PM  BREAKOUT SESSION 1

**IP1: The Controversial QALY: Is There a Middle Ground in the Debate?  New Orleans Theater, Mid-Level Entrance**  
**Moderator:** Jennifer Bright, MPA, Innovation and Value Initiative, Alexandria, VA, USA  
**Panelists:** Lou Garrison, PhD, University of Washington, Seattle, WA, USA; Eleanor M. Perfetto, PhD, MS, National Health Council, Washington, DC, USA; Anna Kaltenboeck, MA, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**IP2: Replication of Randomized Controlled Trials Using Real-World Data: What Does Good Look Like?  Rooms 393-394 (3rd Floor)**  
**Moderator:** Marc Berger, MD, Consultant, New York, NY, USA  
**Panelists:** David Martin, MD, MPH, US Food and Drug Administration, Silver Spring, MD, USA; Sebastian Schneeweiss, MD, ScD, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; David Thompson, PhD, Syneos Health, Manchester, MA, USA

**IP3: Can Health Plans Address the Challenges to Accommodating the Growing Number of Orphan Drugs Entering the Marketplace?  Rooms 388-390 (3rd Floor)**  
**Moderator:** James Chambers, PhD, MPharm, MSc, Tufts Medical Center, Boston, MA, USA  
**Panelists:** Paul Melmeyer, MPP, National Organization for Rare Disorders (NORD), Washington, DC, USA; Susan A. Cantrell, CAE, Academy of Managed Care Pharmacy, Alexandria, VA, USA; Chris L. Pashos, PhD, Abbvie, Cambridge, MA, USA

**W1: Early Prediction of Survival Outcomes—Modeling Approaches for Translation of Tumor Response to Long-Term Clinical Benefits in Early Stage Cancer  Rooms 278-282 (2nd Floor)**  
**Discussion Leaders:** Andrew Briggs, DPhil, University of Glasgow, Glasgow, Scotland, UK; Min Huang, PhD, Merck & Co., Inc., North Wales, PA, USA; Jing Zhao, PhD, Merck & Co., Inc., North Wales, PA, PA; Scott D. Ramsey, MD, PhD, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA

**W2: An Analytic Approach to Incorporating Patient Preferences into Value Elements for Economic Evaluation  Rooms 395-396 (3rd Floor)**  
**Discussion Leaders:** Susan dosReis, PhD, University of Maryland School of Pharmacy, Baltimore, MD, USA; Julia F. Slejko, PhD, University of Maryland School of Pharmacy, Baltimore, MD, USA; Darius N. Lakdawalla, PhD, University of Southern California, Los Angeles, CA, USA; Richard J. Willke, PhD, ISPOR, Lawrenceville, NJ, USA

**P1: Artificial Intelligence Studies  Rooms 391-392 (3rd Floor)**

11:00 - 11:15  **AI1**  An Innovative Artificial Intelligence Application in Disease Screening: An Opportunity to Improve Maternal Healthcare in an Underdeveloped Rural Area  
Shen JY1, Chen JB2, Liu ZR2, Song J2, Wong SY3, Wang XL4, Sui MG5, Magodoro I6, Akinwunmi B7, Zhang C7, Liu Q8, Ming WK9  
1School of Medicine, Jinan University, Guangzhou, China; 2School of Information Science and Technology, Jinan University, Guangzhou, China; 3School of International Studies, Sun Yat-sen University, Guangzhou, China; 4School of Journalism and Communication, Jinan University, Guangzhou, China; 5School of Economics, Jinan University, Guangzhou, China; 6Centre for Global Health, Massachusetts General Hospital, Boston, MA, USA; 7Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Boston, MA, USA; 8School of Public Health, The University of Hong Kong, Hong Kong, China; 9Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

11:15 - 11:30  **AI2**  Leveraging Machine-Assistance to Replicate a Systematic Review  
Michelson M1, Ross M1, Minton S1, 1Evid Science, El Segundo, CA, USA; 2Inferlink, El Segundo, CA, USA

11:30 - 11:45  **AI3**  Discriminative Ability of Commonly Used Indices to Predict Outcomes After Total Knee Replacement: A Comparison of Demographics, Provider Volume, ASA Score, Charlson, Elixhauser and Functional Comorbidity Index  
Huang Z1, Ruppenkamp J1, Krishnan D2, Holy CE2, 1Johnson & Johnson, New Brunswick, NJ, USA; 2Johnson & Johnson, Garner, NC, USA; 1Mu-sigma, Bangalore, India

11:45 - 12:00  **AI4**  Economic Impact Analysis and Predictive Modeling Identifying Risk Factors for Opioid Use Disorder in Medicaid Managed Care Populations  
Jones J, Gao W; Keleti D, Chen Y, Mistry P, AmeriHealth Caritas, Philadelphia, PA, USA

* Indicates an advanced session.
**Monday May 20**

**P2: Cardiovascular Studies  Rooms 383-385 (3rd Floor)**

11:00 - 11:15  **CV1** Assessment of the High Risk and Unmet Need in Patients with CAD and Type 2 Diabetes (ATHENA): US Healthcare Resource Use and Cost in the Diabetes Collaborative Registry

Wittbrodt E1, Bhalla N1, Andersson Sundell K1, Hunt P2, Mellstrom C3, Gao Q4, Dong L5, Cavender M6, Wong ND7, AstraZeneca, Wilmington, DE, USA; AstraZeneca, Molndal, Sweden; AstraZeneca, Gaithersburg, MD, USA; Baim Institute for Clinical Research, Boston, MA, USA; University of North Carolina, Chapel Hill, NC, USA; University of California, Irvine, CA, USA

11:15 - 11:30  **CV2** Adverse Reaction Signal Detection for Statins in Regional Healthcare Database Using Tree-Based Scan Statistic Method

Li H1, Zhang L2, Zhan S3, 1West China Second Hospital, Sichuan University, chengdu, 51, China, 2West China Second Hospital, Sichuan University, Chengdu, China, 3Peking University Health Science Center, Beijing, China

11:30 - 11:45  **CV3** Variations in Healthcare Resource Use and Expenditures By Age in Patients Under Age 65 Newly Diagnosed with Paroxysmal Supraventricular Tachycardia (PSVT) in the United States

Sacks NC1, Everson KA2, Cvr PL3, Emden M4, Preib M5, Wood DR6, Pokorney SD7, Tufts University School of Medicine, Boston, MA, USA; Precision Health Economics, Los Angeles, CA, USA; Precision Xtract, Boston, MA, USA; Milestone Pharmaceuticals, Inc., Saint-Laurent, QC, Canada; Duke University School of Medicine, Durham, NC, USA

11:45 - 12:00  **CV4** Budget Impact of Changing Oral Anticoagulant Prescribing to Prevent Atrial-Fibrillation-Related Stroke in England

Orlowski A1, Wu JH2, Wilkins J3, Smith W4, 1Imperial College Health Partners, London, UK, 2University of Leeds, Leeds, UK

12:00PM - 1:30PM  **LUNCH IN THE EXHIBIT HALL** Poster and Exhibit Hall, Hall H

12:00PM - 2:00PM  **EXHIBITS AND POSTER PRESENTATIONS VIEWING – SESSION 1** Poster and Exhibit Hall, Hall H

12:15PM – 1:15PM  **ISPOR BOOTH EVENT** Poster and Exhibit Hall, Booth #407

Learn. Apply. Advance. Navigate ISPOR’s Educational Offerings With the Education Council Chair—Karen Rascati, RPh, PhD.

12:30PM - 1:30PM  **EDUCATIONAL SYMPOSIUM** New Orleans Theater, Mid-Level Entrance

Challenges of Economic Modeling in Rare Diseases and Assessment of Value in SMA

Sponsored by: Biogen

Moderator: Robin Thompson, PhD, MSc, Biogen, Baar, Switzerland

Speakers: Chris Knight, MSc, RTI Health Solutions, Manchester, LAN, UK; Kenneth Hobby, MBA, Cure SMA, Elk Grove Village, IL, USA; Mark Connolly, PhD, Global Market Access Solutions, Mooresville, NC, USA

12:30PM - 1:45PM  **ISPOR FORUMS**

**ISPOR Oncology Special Interest Group: Improving the Availability and Quality of Utility Estimates for the Post-Progression Period in Oncology Models: Recommendations Based on a Systematic Review**

Rooms 388-390 (3rd Floor)

The forum discusses a systematic review of utility estimates for the post-progression period for all oncology indications. The discussion leaders will present: 1. An overview of the methods and results: Out of a total of 4839 published articles and 176 HTAs in all oncology indications; 350 publications and 60 technology appraisals were included. Review included details on study type, utility measure, sample size, number and timing of assessments, quality assessments, potential biases, utility estimates of caregivers/family members, and approaches to modeling post-progression period. Challenges/opportunities for collecting high quality utility data post-progression in RCTs and observational studies, including insights from an oncologist and ASCO member. Some “good practice” examples, and recommendations for future studies. This forum will be of value for researchers interested in QOL research, health utility estimation, economic evaluation, and/or HTA in oncology indications. Participants are invited to contribute to the discussion and make suggestions for future research methods.

**ISPOR Health Preference Methods Special Interest Group: Frontiers in Health Preference Research**

Room 397 (3rd Floor)

This forum will share a selection of novel methods and applications in health preference research. Preference methods are being used to collect evidence on preferences for treatment outcomes, health states, and health policies. The tools available to generate and analyze preference data have been advancing rapidly and this forum is intended to share such advances with ISPOR members. In this forum, the leadership of the Health Preference Research Special Interest Group selected studies that are novel because of how they were conceived, how they were implemented, or the way the resulting
data were analyzed. The forum will give expert preference researchers the opportunity to describe their work and how it contributes to the science of health preference research or to the implementation of the results in healthcare. After the presentations are concluded, the presenters will have an informal discussion with attendees as they enjoy lunch.

**ISPOR Latin America Consortium Regional Update**  *Room 292 (2nd Floor)*
Latin American delegates are encouraged to stop by and take the opportunity to meet with colleagues from the Latin America Consortium and discuss working committees and chapter updates, learn more about ISPOR Latin America 2019 in Bogotá, Colombia, follow up on the latest developments in HEOR and Health Policy from the region or talk to the Latin America team that will be available onsite for questions.

**ISPOR Open-Source Models Special Interest Group: Lies, Damned Lies, and Cost-Effectiveness**  *Rooms 391-392 (3rd Floor)*
Cost-effectiveness and disease models are often statistically sophisticated and may be seen as opaque by stakeholders. Open-source models (OSM) would encourage greater transparency and facilitate the reuse and updating of the best/most useful models. Per ISPOR-SMDM and EUnetHTA, OSM will advance modeling methods by reducing bias, increasing transparency, improving model access, and allowing for faster access to critical knowledge. With openness and sharing come issues of copyright and access and a need to define how model sharing can be achieved in an equitable manner. The pros and cons of OSMs and the proposed mission of the Open Source Model SIG will be debated amongst SIG members.

**ISPOR Real-World Evidence Transparency Collaborative – The Case for Study Registration**  *Rooms 393-394 (3rd Floor)*
Real-world data (RWD) and real-world evidence (RWE) are becoming more accepted as ways to generate evidence for decision making. However, there are still questions about the quality and statistical rigor of the evidence provided by observational secondary studies. One way to help determine the quality of these types of studies is to have more transparency of the hypothesis and methods used to collate and analyze the data. This forum will present the current efforts of an ISPOR-led collaborative intending to move the needle on observational secondary study registration as a means to increase transparency. The progress and deliberations of this collaborative will be reviewed and discussed here, including concrete recommendations for next steps which will form the basis of a whitepaper. Feedback from the audience will be encouraged and collected to help inform the collaborative as it moves forward.

**ISPOR Asia Consortium – Drug Pricing**  *Rooms 395-396 (3rd Floor)*
Drug pricing is a complex issue and cost concerns affect the choices patients make about their care and lead to non-adherence. Value-based drug pricing and innovative negotiation agreement between the government and industry is a promising strategy to help improve patient outcomes at an affordable cost. How does the drug-pricing system change along with universal and value-driven coverage? How do we address rising drug costs while ensuring meaningful access to high-value care? In this session, our experts from Asia and beyond will address key issues surrounding drug pricing in their countries, such as main drivers of high drug-prices, drug pricing policies, the process of drug price negotiation, inherent challenges for various stakeholders, and possible solutions to form valued-based fair drug prices.
Monday, May 20

3:15PM - 3:45PM Break, Exhibits & Research Poster Presentations Viewing—Session 2 Poster and Exhibit Hall, Hall H

3:15PM - 4:15PM ISPOR Booth Event Poster and Exhibit Hall, Booth #407
Global Networks: Explore the Benefits of Transitioning From Conference Registrant to Member

3:30PM - 4:30PM ISPOR Forums Room 397 (3rd Floor)

ISPOR Student Research Spotlight
This revamp of the Student Research Showcase will allow for increased participation and interaction as it will feature 8 of the top-scored student outcomes research studies submitted for the conference. Attendees of the event will rotate to each presenter and listen to a 3- to 5-minute elevator pitch of the summary of the research study, the methods, challenges, the so what, conclusions, and the relevance of the research to the conference theme of Rapid. Disruptive. Innovative: A New Era in HEOR. Student Network Advisor, Zeba Khan and Faculty Advisor Council Chair, Laura Pizzi will serve as moderators and provide their feedback for each presenter.

3:30PM - 7:00PM Research Poster Presentations—Session 2 Poster and Exhibit Hall, Hall H

3:45PM - 4:45PM Breakout Session 2

Moderator: Jill E. Sackman, DVM, PhD, Exponent, Farmington Hills, MI, USA
Panelists: Jessica Shepherd, MD, MBA, Baylor University Medical Center, Dallas, TX, USA; Colleen Riley, OD, Stryker, Mahwah, NJ, USA; Lori G. Cohen, JD, Greenberg Traurig, LLP, Atlanta, GA, USA

IP5: Are Novel Concepts of Value Ready for Prime Time? Rooms 395-396 (3rd Floor)
Moderator: Jeroen P. Jansen, PhD, Innovation and Value Initiative, Los Angeles, CA, USA
Panelists: Darius N. Lakdawalla, PhD, University of Southern California, Los Angeles, CA, USA; Michael Drummond, MCom, DPhil, University of York, Heslington, York, UK; Sachin Kamal-Bahi, PhD, SKB Consulting Inc., Philadelphia, PA, USA

Moderator: Lotte Steuten, PhD, MSc, Fred Hutchinson Institute for Cancer Outcomes, Seattle, WA, USA
Panelists: Sean R. Tunis, MD, MSc, Center for Medical Technology Policy, Baltimore, MD, USA; Neal Meropol, MD, Flatiron Health, New York, NY, USA; Daryl Pritchard, PhD, Personalized Medicine Coalition, Washington, DC, USA

W3: Using PFS to Determine the Cure Potential of New Innovative Therapies in DLBCL Rooms 393-394 (3rd Floor)
Discussion Leaders: Federico Felizzi, PhD, F. Hoffmann La Roche, Basel, Switzerland; Per-Olof Thuresson, MPharm, MSc, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Daniel Sheinson, PhD, Genentech, Inc., San Francisco, CA, USA; Anirban Basu, PhD, University of Washington, Seattle, WA, USA

W4: Proactive: Linking Design, Analysis and Interpretation of PROs in Clinical Trials Rooms 391-392 (3rd Floor)
Discussion Leaders: Stephanie Manson, PhD, Novartis, East Hanover, NJ, USA; Donald Stull, PhD, Head, RTI Health Solutions, Research Triangle Park, NC, USA; Jessica K. Roydhouse, PhD, US Food and Drug Administration, Silver Spring, MD, USA; Pallavi Mishra-Kalyani, PhD, US Food and Drug Administration, Silver Spring, MD, USA

3:45 - 4:00
MS1 A Comparison of Three and Four State Economic Models for Cost-Effectiveness Analysis in Oncology
Incerti D., Jansen JP, Innovation and Value Initiative, Los Angeles, CA, USA

4:00 - 4:15
MS2 An Updated Two-Year Survival Analysis of Axicabtagene Ciloleucel (AXI-CEL) in Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL)
Diakite I., Lin VV, Klijn S, Navale L, Purdum AG, Fenwick E, Botteman M, van Hout B, 1Pharmerit International, Bethesda, MD, USA; 1Kite, A Gilead Company, Santa Monica, CA, USA; 1Pharmerit International, Rotterdam, Netherlands; 1Pharmerit International, Oxford, UK; 1University of Sheffield, Sheffield, UK

4:15 - 4:30
MS3 New Methodologies in Parametric Network Meta-Analyses (PNMA): Multi-Arm Correction for Random Effects and General Population Mortality (GPM)
van Beekhuizen S, van Oostrum I, Ouwens DM, Heeg B, 1Ingress-Health, Rotterdam, Netherlands; 1AstraZeneca, Mölndal, Sweden

*Indicates an advanced session.
Monday May 20

4:30 - 4:45  **MS4**  A Comparison of the Partitioned Survival and Multistate Extrapolation Methods: A Case Study Based on the Gastric Cancer Trial Attraction-2  
**Klijn S**1, Bertwistle D2, Contente M3, Kroep S4, 1Pharmerit International, Rotterdam, ZH, Netherlands, 2Bristol-Myers Squibb, Uxbridge, Middlesex, UK, 3Bristol-Myers Squibb Pharmaceuticals, Ltd, Uxbridge, LON, UK, 4Pharmerit International, Rotterdam, Netherlands

P4: Rare & Orphan Diseases Studies  **Rooms 386-387 (3rd Floor)**

3:45 - 4:00  **RO1**  Health-Related Quality of Life in Hereditary Transthyretin Amyloidosis: Qualitative Interviews with Patients  
**Raymond K**1, Lovley A1, White MK1, Guthrie S1, Pollock M2, 1Optum, Johnston, RI, USA, 2Akcea Therapeutics, Boston, MA, USA

4:00 - 4:15  **RO2**  Assessing the Relationship Between Lifelong Value and Pricing for Orphan Drugs in Ultra-Rare Diseases  
**Dabbous O**1, Zhou Z1, Tang C1, Harvey M1, Wu EQ2, Arjunji R3, 1AveXis, Inc., Bannockburn, IL, USA, 2Analysis Group, Inc., London, UK, 3Analysis Group, Inc., New York, NY, USA, 4Analysis Group, Inc., Boston, MA, USA

4:15 - 4:30  **RO3**  Do Health Plans Cover Orphan and Non-Orphan Drugs Differently? An Empirical Analysis  
**Margaretos N**1, Panzer A, Neumann PJ, Chambers J, Tufts Medical Center, Boston, MA, USA

4:30 - 4:45  **RO4**  Cost-Effectiveness Analysis of rFVIIIFc, Pegylated rFVIII, and Emicizumab for the Prophylactic Treatment of Severe Hemophilia A Patients Without Inhibitors in the United States  
**Li N**1, 2, Bullement A2, McMordie S1, Hatswell AJ1, Wilson K1, 1Sanofi, Waltham, MA, USA, 2Delta Hat, Nottingham, UK, 3Swedish Orphan Biovitrum AB, Stockholm, Sweden

5:00PM - 6:00PM  **ISPOR FORUMS**

ISPOR New Professional Event: Career Advice Across the Globe  **Room 292 (2nd Floor)**
The New Professional Event, Career Advice Across the Globe, provides both New Professional and soon-to-graduate Student members with the opportunity to hear first-hand experiences from established ISPOR members around the world. Each conference focuses on a different career-related topic based largely from the results of our New Professional Interest Survey. This session’s topic is: “Good Practices for HTA: What is Out There and How Can I Use it?”

5:00PM - 6:00PM  **BREAKOUT SESSION 3**

IP7: How Much Should We—and Can We—Pay for Gene Therapies?  **Rooms 278-282 (2nd Floor)**  
**Moderator:** Jason Shafrin, PhD, Precision Health Economics, Los Angeles, CA, USA  
**Panelists:** Anupam B. Jena, MD, PhD, Harvard Medical School, Boston, MA, USA; Jeremy Schafer, PharmD, MBA, Precision for Value, Chicago, IL, USA; Ramesh Arjunji, PhD, AveXis, Inc., Bannockburn, IL, USA

IP8: Can We Make Global Value Assessments More Flexible and Comprehensive?  **Rooms 388-390 (3rd Floor)**  
**Moderator:** Peter J. Neumann, ScD, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA  
**Panelists:** Finn Berlum Kristensen, MD, PhD, University of Southern Denmark, Hillerød, Denmark; Mark Sculpher, PhD, University of York, York, UK; Devin Incerti, PhD, Precision Health Economics, Los Angeles, CA, USA

**Moderator:** Stacey Kowal, MSc, IQVIA, Fairfax, VA, USA  
**Panelists:** Richard Chapman, PhD, MS, Institute for Clinical and Economic Review, Boston, MA, USA; Alex Upton, MSc, Bayer, Reading, UK; John Watkins, PharmD, MPH, BCPS, Blue Cross, Bothell, WA, USA

W5: Quantitative Patient Preferences and Values With Limited Information: Lessons From the Non-Health Benefits-Transfer Literature  **Rooms 393-394 (3rd Floor)**  
**Discussion Leaders:** F. Reed Johnson, PhD, Duke Clinical Research Institute, Durham, NC, USA; Juan Marcos Gonzalez Sepulveda, PhD, Duke University, Durham, NC, USA; Bjorn Bolinder, MBA, BSc, AstraZeneca, Gaithersburg, MD, USA

W6: Artificial Intelligence for Next Generation Epidemiology and Outcomes Research  **Rooms 395-396 (3rd Floor)**  
**Discussion Leaders:** Craig S. Roberts, PharmD, MPA, MBA, Merck & Co., Inc., Kenilworth, NJ, USA; Benjamin Birnbaum, PhD, Flatiron Health, New York, NY, USA; Wanmei Ou, PhD, Merck & Co., Inc., Boston, MA, USA; Kun Huang, PhD, Indiana University and Regenstrief Institute, Indianapolis, IN, USA

Indicates an advanced session.
Monday  May 20

**P5: Adherence, Persistence and Compliance Studies  Rooms 386-387 (3rd Floor)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00</td>
<td><strong>AD1</strong> Treatment Experiences of Patients with Schizophrenia: Findings from a Qualitative Focus Group Study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bessonova L1, Sajatovic M2, Saucier C3, Weiden PJ, Carpenter-Conlin J, O'Sullivan AK, White MK, Veiligen DI, Alkermes, Inc., Waltham, MA, USA, University Hospitals Cleveland Medical Center, Cleveland, OH, USA, Optum, Johnston, RI, USA, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA</td>
<td></td>
</tr>
<tr>
<td>5:15</td>
<td><strong>AD2</strong> Examining the Association Between Provider Outreach and Patients’ Statin Refill Behavior for Patients Within a Medicare Advantage with Prescription Drug (MAPD) Coverage Population</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chikermane S1, Nguyen MK, Esse T, Abughosh S, University of Houston, Houston, TX, USA, CareAllies, Richmond, TX, USA, CareAllies, Houston, TX, USA</td>
<td></td>
</tr>
<tr>
<td>5:30</td>
<td><strong>AD3</strong> Food Insecure Cancer Survivors Are More Likely to Forgo or Delay Medical Care</td>
<td></td>
</tr>
<tr>
<td>5:45</td>
<td><strong>AD4</strong> The Impact of Medicare Star Rating Adherence Measures on Medication Adherence for Targeted and Non-Targeted Medications</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Parekh N1, Munshi K2, Hernandez I1, Gellad WF, Henderson R, Shrank WH, UPMC Center for High-Value Health Care, Pittsburgh, PA, USA, Express Scripts, Memphis, TN, USA, University of Pittsburgh, Pittsburgh, PA, USA, Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA, UPMC Insurance Services Division, Pittsburgh, PA, USA</td>
<td></td>
</tr>
</tbody>
</table>

**P6: Reimbursement and Access Policy Studies  Rooms 383-385 (3rd Floor)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00</td>
<td><strong>RE1</strong> The Impact of Patient Copay on Abandonment of Prescribed Antiepileptic Drug Treatment in a Pediatric Patient Population</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mehta D1, Davis M2, Epstein A3, Lee A1, Sunovion Pharmaceuticals Inc., Marlborough, MA, USA, Medicus Economics, LLC, Milton, MA, USA</td>
<td></td>
</tr>
<tr>
<td>5:15</td>
<td><strong>RE2</strong> The Impact of Financial Access to Healthcare on Productivity Loss and Associated Out-of-Pocket Costs Among Cancer Survivors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Xiong X, Wu J, Lu K, China Pharmaceutical University, Nanjing, China, Presbyterian College, Clinton, SC, USA, University of South Carolina College of Pharmacy, Columbia, SC, USA</td>
<td></td>
</tr>
<tr>
<td>5:30</td>
<td><strong>RE3</strong> At What Price Does CAM2038’s Effectiveness Align with Value When Treating Opioid Use Disorder in the United States: A Cost-Utility Model</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kumar VM, Ellis A, Samur S, Chapman R, Institute for Clinical and Economic Review, Boston, MA, USA</td>
<td></td>
</tr>
<tr>
<td>5:45</td>
<td><strong>RE4</strong> US Commercial Health Plans Cite International Health Technology Assessments in Their Specialty Drug Coverage Decisions with Different Frequencies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shah V, Chambers J, Panzer A, Margaretos N, University of Manchester, London, UK, Tufts Medical Center, Boston, MA, USA</td>
<td></td>
</tr>
</tbody>
</table>

**6:00PM - 7:00PM**  **ISPOR BOOTH EVENT** Poster and Exhibit Hall, Booth #407 Value in Health’s 20th Anniversary Celebration

**6:00PM - 7:00PM**  **POSTER AUTHOR DISCUSSION HOUR – SESSION 2** Poster and Exhibit Hall, Hall H

**6:00PM - 7:30PM**  **WELCOME RECEPTION IN THE EXHIBIT HALL** Poster and Exhibit Hall, Hall H

Be sure to attend the official exhibit hall opening and welcome reception at ISPOR 2019. Greet old friends and colleagues, make new connections and take advantage of the chance to meet one-on-one with industry leaders who are available to discuss and review the latest innovative products in the health economics and outcomes research (HEOR) field. Over 100 exhibitors and sponsors will be present to help you discover solutions and discuss the trends in HEOR. In addition, there will be more than 350+ posters available for viewing during the reception. A live local Bourbon Street Band will get the party started along with complimentary wine, beer, soft drinks, and hors d’oeuvres. We look forward to greeting you at the welcome reception!
Monday, May 20

6:00PM – 9:00PM  
**“DINE-AROUND” WITH WOMEN IN HEOR**  
*Offsite*

Enjoy the perfect opportunity to sample some of New Orleans’ delicious foods while engaging in conversations with your colleagues from the Women in Health Economics and Outcomes Research (HEOR) Initiative. We are offering dine-around options during the conference. This special dining option is limited to groups of no more than 10 attendees and features a variety of New Orleans’ restaurants. Each group has a designated dinner host(s) who is coordinating the event at that restaurant venue. Participants will cover their own cocktails and dinner. Tables fill up quickly, so please be sure to visit the ISPOR Women in HEOR Initiative webpage (https://www.ispor.org/strategic-initiatives/more/women-in-heor) to reserve your seat!

7:30PM – 9:00PM  
**ISPOR GLOBAL NETWORKS RECEPTION**  
*New Orleans Theater Foyer, Mid-Level*

ISPOR invites you to a unique networking opportunity – an ISPOR Global Networks Reception! Meet with members of ISPOR Consortia in Asia, Latin America and Central and Eastern Europe, as well as ISPOR Networks in the Middle East and Africa, to exchange knowledge, share experiences, and learn about ISPOR global groups during this joint event. This reception is open to all meeting attendees interested in our Global Networks. Join us for this truly multicultural experience and connect with regional experts in health economics, learn how members of the ISPOR Global Networks benefit from and contribute to ISPOR, and find out how you can also get involved!
Tuesday  May 21

7:00AM - 6:30PM  **REGISTRATION HELP DESK HOURS**  Hall H Lobby

7:00AM - 8:00PM  **COAT ROOM HOURS**  Hall H Lobby

7:00AM - 8:00PM  **MULTI-FAITH PRAYER ROOM**  Room 298 (2nd Floor)

7:00AM - 8:00PM  **NURSING MOTHERS’ ROOM**  Room 299 (2nd Floor)

7:15AM - 8:15AM  **EDUCATIONAL SYMPOSIUM**  Rooms 278-282 (2nd Floor)

---

7:15AM - 8:15AM  **Concept to Coverage: Utilization of Value Assessment Frameworks in Payer Decision-Making**

*Sponsored by: Xcenda*

*Moderator: Kristen Migliaccio-Walle, BS, Xcenda, Palm Harbor, FL, USA*

*Speakers: Surya Singh, MD, Sing Healthcare Advisors, Lexington, MA, USA; Amir Bassiri, BA, MSW, New York, NY, USA*

8:00AM - 6:00PM  **SPEAKER READY ROOM**  Room 277 (2nd Floor)

8:30AM - 10:30AM  **WELCOME & SECOND PLENARY SESSION**  New Orleans Theater, Mid-Level Entrance

---

**Welcome from ISPOR President**

Federico Augustovski, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina

**Welcome from ISPOR Chief Science Officer**

Richard J. Willke, PhD, ISPOR, Lawrenceville, NJ, USA

**Incoming Presidential Address**

Nancy Devlin, PhD, University of Melbourne, Melbourne, Australia

**2019 ISPOR Marilyn Dix Smith Leadership Award**

*AWARDEE: Josephine Mauskopf, PhD, RTI Health Solutions, Research Triangle Park, NC, USA*

**SECOND PLENARY SESSION: MEDICAL DEVICE INNOVATION AND REGULATION: TURBOCHARGED FOR SUCCESS?**

*Moderator: Laurie Burke, MPH, LORA Group, LLC, Royal Oak, MD, USA*

*Speakers: Stephanie Christopher, MA, Medical Device Innovation Consortium, Washington, DC, USA; Paul Coplan, ScD, MBA, Johnson & Johnson, New Brunswick, NJ, USA; Stephen A. Hull, MHS, Hull Associates LLC, Rockland, MA, USA; Harindra Wijeysundera, MD, PhD, CADTH, Ottawa, ON, Canada*

10:30AM - 11:00AM  **BREAK, POSTERS AND EXHIBIT VIEWING**  Poster and Exhibit Hall, Hall H

10:30AM - 11:30AM  **ISPOR BOOTH EVENT**  Poster and Exhibit Hall, Booth #407

ISPOR Membership: How to Get More Involved

10:30AM - 2:00PM  **RESEARCH POSTER PRESENTATIONS – SESSION 3**  Poster and Exhibit Hall, Hall H

10:30AM - 7:30PM  **POSTER & EXHIBIT HALL HOURS**  Poster and Exhibit Hall, Hall H

11:00AM - 12:00PM  **BREAKOUT SESSION 4**

**IP10: The Rise of ICER Means the Loss of Choice: True, False or Uncertain?**  Rooms 278-282 (2nd Floor)

*Moderator: Denise Kruzikas, PhD, MPH, AESARA, Island Lake, IL, USA*

*Panelists: Robert W. Dubois, MD, PhD, National Pharmaceutical Council, Washington, DC, USA; Michael Sherman, MD, MBA, MS, Harvard Pilgrim HealthCare, Wellesley, MA, USA; Ron Akehurst, DSc, Hon MFPHM, BresMed Health Solutions, Sheffield, UK*

**IP11: MCDA or Weighted CEA Based on the QALY? Which is the Future for HTA Decision Making?**

*Rooms 388-390 (3rd Floor)*

*Moderator: Nancy Devlin, PhD, University of Melbourne, Melbourne, Australia*

*Panelists: Charles Phelps, PhD, University of Rochester, and Gualala, CA, USA; Adrian Towe, MA, MPhil, Office of Health Economics, London, UK*
IP12: Controversies Around the Use of Patient-Reported Measures in Oncology: What Are the Benefits, Risks, and Barriers to Implementing PR-PMS in Value-Based Payment Programs?  
Rooms 391-392 (3rd Floor)  
Moderator: Theresa Schmidt, MA, Discern Health, Baltimore, MD, USA  
Panelists: W. Garth Callaghan, Napkin Notes Dad, Glen Allen, VA, USA; Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC, USA; Cynthia Grossman, PhD, Biogen, Cambridge, MA, USA  

W7: How to Tackle the Estimation of Treatment Impact in the Presence of Differential Withdrawal and Missing Data Among Study Arms?  
Rooms 393-394 (3rd Floor)  
Discussion Leaders: Necdet Gunsoy, PhD, GlaxoSmithKline (GSK), Uxbridge, BKM, UK; Neil Hawkins, PhD, MSc, MBA, CStat, University of Glasgow, Scotland, UK; Helene Karcher, PhD, PAREXEL Access Consulting, London, UK  

W8: Assessing the Value of Rare Disease Treatments: Global Lessons From Recent Case Studies  
Rooms 395-396 (3rd Floor)  
Discussion Leaders: James Wu, MSc, MPH, Amgen, Thousand Oaks, CA, USA; Clifford Goodman, PhD, The Lewin Group, Falls Church, VA, USA; Louis P. Garrison, PhD, Strategic Pharmacy Innovations, Seattle, WA, USA; Paul Melmeyer, MPP, National Organization for Rare Disorders (NORD), Washington, DC, USA  

P7: Clinical Outcomes Assessment Studies  
Rooms 386-387 (3rd Floor)  
11:00 - 11:15  
CL1 Defining and Demonstrating a Child-Caregiver Dyad Questionnaire Administration Approach to the Assessment of Pediatric Health-Related Quality of Life  
Turner-Bowker D1, Yaworsky A1, Lamoureux R2, Kelly M1, Palladino A1, Love E1, Loftus J1, Adelphi Values, Boston, MA, USA; 2Adelphi Values, North Chelmsford, MA, USA.  
11:15 - 11:30  
CL2 Identifying Symptoms Clusters Among Pediatric Kidney Disease Patients Using Promis® Computer Adaptive Tests  
Peipert J1, Chapman RS, Langer M, Cella D, Lai JS, Northwestern University, Chicago, IL, USA.  
11:30 - 11:45  
CL3 Understanding the Patient Voice in Comparative Effectiveness Studies: The Role of Benchmark Comparisons  
Rendas-Baum R1, Laird B1, Rychlec K1, Brown JE2, Bayliss M1, Optum Patient Insights, Johnston, RI, USA; OptumRx, Minneapolis, MN, USA.  
11:45 - 12:00  
CL4 Minimal Clinically Important Difference: How International Patients View Pain, Distress and Treatment Outcomes  
Du Y1, Jones SMW2, Bell-Brown A1, Unger JM2, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA.  

P8: Medical Technology Studies  
Rooms 383-385 (3rd Floor)  
11:00 - 11:15  
MT1 Cost-Effectiveness of Robotic-Assisted Unicompartmental Knee Arthroplasty (R-Uuka) Compared to Traditional Unicompartmental Knee Arthroplasty (t-Uuka)  
11:15 - 11:30  
MT2 A Cost-Effectiveness Analysis of Posterior Facet Versus Pedicle Screw Fixation for Lumbar Spinal Fusion  
Buttermann G1, Hollmann S2, Arpino JM2, Ferko N2, ‘Midwest Spine and Brain Institute, Stillwater, MN, USA; 2Cornerstone Research Group Inc., Burlington, ON, Canada.  
11:30 - 11:45  
MT3 The Effectiveness of Capnography on Clinically Important Outcomes from Opioid-Induced Respiratory Depression: A Literature Review  
Tilli T1, Baginska E2, ‘BD - Canada, Mississauga, ON, Canada; 2BD - Canada, Mississauga, ON, Canada.  
11:45 - 12:00  
MT4 Cost Utility Analysis Update of Deep Brain Stimulation vs Best Medical Treatment in the Management of Parkinson Disease with Early Motor Complications in Colombia  
Rueda M1, Arcos J1, Tellez J, Valencia J1, ‘Clinica Soma, Medellin, Colombia; 1Medtronic Colombia, Bogotá, Colombia; 2Medtronic Colombia, Medellin, Colombia; 3Medtronic, Miami, FL, USA.  

12:00PM – 1:30PM  
LUNCH IN THE POSTER & EXHIBIT HALL  
Poster and Exhibit Hall, Hall H  

12:00PM - 2:00PM  
EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION 3  
Poster and Exhibit Hall, Hall H
### Tuesday May 21

#### 12:30 PM - 1:30 PM  **EDUCATIONAL SYMPOSIUM**  
**Rooms 278-282 (2nd Floor)**

**Cell and Gene Therapy - Value and Access**  
*Sponsored by: Analysis Group, Inc.*

*Moderator: Michael Kuehn, RPh, MBA, GfK, New York, NY, USA*  
*Speakers: Michael Sherman, MD, MBA, MS, Harvard Pilgrim HealthCare, Wellesley, MA, USA; Richard Chapman, PhD, MS, Institute for Clinical and Economic Review, Boston, MA, USA; Eric Q. Wu, PhD, Analysis Group, Inc., Boston, MA, USA; Hongbo Yang, PhD, Analysis Group, Inc., Boston, MA, USA*

#### 12:30 PM - 1:45 PM  **ISPOR FORUMS**

**ISPOR Digital Health Special Interest Group**  
**Rooms 393-394 (3rd Floor)**

One of challenges of the dramatic growth of digital health technologies is the lack of established and reliable methodological approaches to properly assess their value. We are forming the Digital Health Special Interest Group to create an opportunity for ISPOR members to address this and other topics in the field. Some of the digital health issues we will consider include: a universal definition; identifying the types and appropriateness of evidence currently used for evaluation; suggesting the best methods for future evaluations; and advancing health economic and outcomes research methods and promoting their use in healthcare decisions. During this presentation, attendees will have the opportunity to discuss topics and specific questions relating to digital health, as well as, to suggest additional ideas. The next steps for the SIG will be outlined. Grab your lunch and join us.

**ISPOR Patient-Centered Special Interest Group: How Can Health Economics and Outcomes Researchers be Torchbearers for Patient Engagement?**  
**Rooms 388-390 (3rd Floor)**

ISPOR members interested in emerging approaches to patient engagement in research are welcome to attend this open discussion. Are you interested in how economics and outcomes researchers can prepare for a new era in HEOR in which patients are guiding research decisions? Grab your lunch and join us for a brief presentation on how patient engagement touches on various aspects of health economics and outcomes research and the value that is added from involving patients in this space. We will discuss the new ISPOR definition of “patient engagement in research,” the revised special interest group structure, as well as identify core topics for the group to develop in the future. Attendees will have the opportunity to discuss and offer ideas on the core topics as well member engagement activities. All attendees are welcome.

**ISPOR Medication Adherence and Persistence Special Interest Group**  
**Rooms 383-385 (3rd Floor)**

Attendees interested in the management of patients with multiple chronic conditions, the clinical and economical challenges associated with poly-pharmacotherapy, and medication adherence are welcome to attend this open discussion. Grab your lunch and join us for a brief presentation on the recently released systematic review on the methods for measuring multiple medication adherence and a proposed follow-up study. Discussion on the topics related to patients with multiple chronic conditions, such as how to evaluate adherence enhancing interventions and their influence on outcomes (eg, quality of life, clinical outcomes, patient satisfaction, resource utilization, etc.), given the limited evidence on how to assess the effects of these interventions along multiple criteria will be presented. Attendees will have the opportunity to discuss ideas for future projects for the special interest group to develop and opportunities for member engagement. All attendees are welcome.

**ISPOR Real-World Evidence Special Interest Group**  
**Rooms 391-392 (3rd Floor)**

Increasingly, healthcare decision makers are looking for new opportunities that can help reduce the time required to bring health innovation to patients. Real-world evidence (RWE) is currently in the spotlight; however, regulators (amongst others) remain cautious as they evaluate how much they can trust RWE. We are forming a new RWE SIG dedicated to increasing awareness, understanding, and rigor and utilization of RWE as an important part of the wider evidence base for healthcare decision making. In order to be successful, ISPOR needs you, its members, to support this initiative, to address known and emerging challenges so that patients ultimately get access to the right treatment, at the right time. This open SIG meeting will present a range of RWE-specific topics to ascertain which concerns require immediate action, whether ISPOR is best placed to contribute to the solution, and to start defining how we collectively might address them. During the meeting, attendees will have the opportunity to contribute their perspectives, suggest alternative topics, and volunteer to help advance the future activities of the SIG.

**ISPOR Personalized Precision Medicine Special Interest Group: Leveraging Real-World Evidence to Address Uncertainty for Transformative and Curative Therapies**  
**Rooms 391-392 (3rd Floor)**

Uncertainty around magnitude and duration of therapeutic effect has posed the fundamental value challenge for advanced gene- and cell-based therapies that promise transformative or curative effect. Real world evidence (RWE) is proposed as a core solution to bridge evidentiary uncertainty at all stages, ranging from regulatory to reimbursement and risk sharing. This panel will debate how to what extent RWE approaches can be used to address uncertainty across the cell and gene therapy lifecycle. After an overview of evidence uncertainties associated with transformative therapies where RWE can address gaps is presented, we will explore how manufacturers are leveraging RWE approaches to demonstrate value and discuss the policy levers needed to integrate RWE at the regulatory and payer level. Lastly, we will highlight lessons from ongoing US work on transformative and curative therapies and recent initiatives.
ISPOR Poland and ISPOR Ukraine Chapters: New Value and Coverage Frameworks for Innovative Medicines in CEE

Rooms 386-387 (3rd Floor)

There is a need to define policy and criteria for making efficient resource allocation for financing of pharmaceuticals in Central and Eastern Europe. What best practices should be considered – multi-criteria decision analysis (MCDA) for innovative medicines, value-based pricing and value based procurement, managed entry agreements? Participants of this interactive Forum will discuss vision towards new trends and how to optimize access and value of innovative medicines in CEE. Interactive participation from the audience is anticipated.

1:00PM - 2:00PM  POSTER AUTHOR DISCUSSION HOUR – SESSION 3  Poster and Exhibit Hall, Hall H

1:00PM - 2:00PM  ISPOR GENERAL BUSINESS MEETING  Room 292 (2nd Floor)

Attendees are invited to attend ISPOR's General Business Meeting, the official business meeting of the Society. Members will learn about ISPOR's recent accomplishments and plans for the future, and have the opportunity to meet board members.

2:15PM - 3:15PM  BREAKOUT SESSION 5

IP13: To Register or Not to Register (The Protocol). That Is the Question in Observational and Big Data Studies, Economic Models, and Cost-Effectiveness Analysis.  Rooms 278-282 (2nd Floor)

Moderator: Federico Augustovski, MD, MSc, PhD. University of Buenos Aires, Buenos Aires, Argentina

Panelists: Rebecca J. Williams, PharmD, MPH, National Institutes of Health, Bethesda, MD, USA; Meindert Boysen, PharmD, MSc, National Institute for Health and Care Excellence (NICE), Manchester, UK; Peter J. Neumann, ScD, Tufts Medical Center, Boston, MA, USA; Marc Berger, MD, Consultant, Inc, New York, NY, USA

IP14: How Can New Outcomes Such as the Ones Derived from Wearables or Patient Experience Reports be Useful in Reimbursement and Coverage Decisions?  Rooms 388-390 (3rd Floor)

Moderator: Helene Karcher, PhD, PAREXEL Access Consulting, London, UK

Panelists: Katja Rudell, PhD, Queen Mary University of London, Chittering, UK; Stephanie A. Regnier, MBA, PhD, Novartis Pharma AG, Basel, Switzerland; Sean R. Tunis, MD, MSc, Center for Medical Technology Policy, Baltimore, MD, USA


Moderator: Karissa M Johnston, PhD, Memorial University, St. John’s, NF, Canada

Panelists: Catherine Davis, PharmD, Bristol-Myers Squibb, Lawrenceville, NJ, USA; Greta Lozano-Ortega, MSc, Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada; Sean D. Sullivan, PhD, MSc, RPh, University of Washington, Seattle, WA, USA

W9: Use of Real-World Data to Extrapolate Survival Estimates for Cost-Effectiveness Analyses in Oncology  Rooms 393-394 (3rd Floor)

Discussion Leaders: C. Daniel Malone, PhD, RPh, University of Arizona, Tucson, AZ, USA; Federico Felizzi, PhD, F. Hoffmann La Roche, Basel, Switzerland; Ning Wu, PhD, Genentech, Inc., San Francisco, CA, USA; Daniel Sheinson, PhD, Genentech, Inc., San Francisco, CA, USA

W10: Developing Standard Core Sets of Clinical Outcome Assessments and Their Related Endpoints for Specific Disease Indications  Rooms 395-396 (3rd Floor)

Discussion Leaders: Meghana Chalasani, MHA, US Food and Drug Administration, Silver Spring, MD, USA; Laura Lee Johnson, PhD, US Food and Drug Administration, Silver Spring, MD, USA; Elektra Papadopoulos, MD, MPH, US Food and Drug Administration, Silver Spring, MD, USA

P9: Infectious Disease Studies  Rooms 386-387 (3rd Floor)

2:15 - 2:30  IN1  The Increased Risks of Non-Hepatic Cancers Among Hepatitis C Virus (HCV) Infected Patients: A Population-Based Cohort Study in the US

Wang W1, Lo Re III V2, Guo Y1, Xiao H4, Brown J1, Park H1, 1University of Florida, College of Pharmacy, Gainesville, FL, USA, 2University of Pennsylvania, Philadelphia, PA, USA, 3University of Florida, College of Medicine, Gainesville, FL, USA, 4Bristol-Myers Squibb, Lawrenceville, NJ, USA

2:30 - 2:45  IN2  Temporal Changes in Cost-Effectiveness for Chronic Hepatitis C Virus Pharmacotherapy

Mattingly J1, Love BL2, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of South Carolina, Columbia, SC, USA

2:45 - 3:00  IN3  One-Year Economic Burden Among Patients with Community-Acquired Pneumonia (CAP) Initially Managed in the Outpatient Setting: A Retrospective US Cohort Study, 2012-2017

Divino VY, Schranz J1, Shah H1, Jiang M4, DeKoven M1, Zilberberg M1, 1IQVIA, Fairfax, VA, USA, 2Nabriva Therapeutics US, Inc., King of Prussia, PA, USA, 3Value Matters, LLC, Ridgefield, CT, USA, 4IQVIA, Falls Church, VA, USA, 5EviMed Research Group, LLC, Goshen, MA, USA

Indicates an advanced session.
Tuesday May 21

3:00 - 3:15  **IN4** Reducing Hospital-Onset Clostridium Difficile Infection: An Agent-Based Modeling Approach to Evaluate Intervention Cost-Effectiveness
Barker A1, Scaria E1, Sadfar N2, **Alagoz O**3, 1University of Wisconsin, Madison, WI, USA, 2William S. Middleton Memorial Veterans Hospital, Madison, WI, USA, 3University of Wisconsin, Middleton, WI, USA

**P10: Drug-Related Public Health Studies**  Rooms 383-385 (3rd Floor)

2:15 - 2:30  **PH1** Risk of Pneumonia Due to Incident Antipsychotic Drug Use Among Parkinson’s Disease Patients
Inguva S1, Yang Y2, Barnard M3, Pittman E3, 1University of Mississippi, University, MS, USA, 2University of Mississippi, University, MS, USA

2:30 - 2:45  **PH2** Dual-Trajectories of Opioid and Gabapentinoid Use and Risk of Subsequent Drug Overdose Among United States Medicare Beneficiaries
Zhou L1, Bhattacharjee S2, Kwoh CK3, Tighe P4, Reisfield GM5, Malone D6, Slack M7, Lo-Ciganic W8, 1University of Arizona, Tucson, AZ, USA, 2University of Florida, Gainesville, FL, USA

2:45 - 3:00  **PH3** A Retrospective Database Analysis of Short-Acting and Long-Acting Opioid Use in Women with Endometriosis: Demographic Characteristics and Prevalence of Use
As-Sanie S1, Soliman AH2, Evans K1, Erpelding N3, Lanier R4, Katz N5, 1University of Michigan, Ann Arbor, MI, USA, 2AbbVie, North Chicago, IL, USA, 3Analgesic Solutions, LLC, Wayland, MA, USA, 4Analgesic Solutions, LLC, Natick, MA, USA

3:00 - 3:15  **PH4** Association Between Polypharmacy and Health-Related Quality of Life Among Cancer Survivors in the United States
Babcock Z1, Vyas A, Caffrey AR, Kogut S, University of Rhode Island, Kingston, RI, USA

3:15PM - 3:45PM  **BREAK AND EXHIBITS VIEWING**  Poster and Exhibit Hall, Hall H

3:30PM - 4:30PM  **ISPOR BOOTH EVENT**  Poster and Exhibit Hall, Booth #407
Tips and Advice for New HEOR Professionals: Meet the Chair—Elisabeth Oehrlein

3:30PM - 7:00PM  **RESEARCH POSTER PRESENTATIONS – SESSION 4**  Poster and Exhibit Hall, Hall H

3:45PM - 4:45PM  **BREAKOUT SESSION 6**

**IP16: Real Option Value for Drugs: Is It Really an Option?**  Rooms 388-390 (3rd Floor)
**Moderator:** Adrian Towse, MA, MPhil, Office of Health Economics, London, UK
**Panelists:** Meng Li, PhD, ScM, University of Southern California, Los Angeles, CA, USA; Jens Grueger, PhD, University of York, Heslington, York, UK

**IP17: Gene Therapy in Hemophilia: Can We Balance the Priorities of Patients, Providers, and Payers?**  Rooms 391-392 (3rd Floor)
**Moderator:** Louis P. Garrison, PhD, University of Washington, Seattle, WA, USA
**Panelists:** Jared Tate, PharmD, Premera Blue Cross, Bothell, WA, USA; Tim Brent, MBA, Hemophilia Foundation, New York, NY, USA; Richard McGee, MD, True North Oncology Consultants, Edmonds, WA, USA

**IP18: Gazing into the HEOR Crystal Ball: What Might Be the Future Directions for HEOR in the 2020s?**  Rooms 278-282 (2nd Floor)
**Moderator:** Finn Berlum Kristensen, MD, PhD, University of Southern Denmark, Hilleroed, Denmark
**Panelists:** Nancy Devlin, PhD, University of Melbourne, Melbourne, Australia; Ross Maclean, MD, MBA, Precision Health Economics, Los Angeles, CA, USA; Andrew Briggs, DPhil, University of Glasgow, Glasgow, Scotland, UK

**W11: Are We Capturing the Entire Picture? – Family Spillover Effects in Economic Evaluation**  Rooms 393-394 (3rd Floor)
**Discussion Leaders:** Sachin Kamal-Bahl, PhD, SKB Consulting Inc., Philadelphia, PA, USA; Pei-Jung Lin, PhD, Tufts Medical Center, Boston, MA, USA; Erru Yang, MS, Genentech, Inc., San Francisco, CA, USA; Annie Kennedy, BS, Parent Project Muscular Dystrophy, Hackensack, NJ, USA

**W12: Approaches to Advance the Value of Patient Preference Information in Medical Product Evaluation**  Rooms 395-396 (3rd Floor)
**Discussion Leaders:** Anindita Saha, BSE, US Food & Drug Administration, Silver Spring, MD, USA; Heather Benz, PhD, US Food and Drug Administration, Silver Spring, MD, USA; Megan Moncur, MS, US Food and Drug Administration, Silver Spring, MD, USA; Laura Lee Johnson, PhD, US Food and Drug Administration, Silver Spring, MD, USA
Tuesday May 21

**P11: Comparative and Cost Analysis**  
Rooms 386-387 (3rd Floor)

3:45 - 4:00  
**CO1**  
A Cost-Utility Analysis of Degarelix in the Treatment of Prostate Cancer in China  
Yang F, Du X, Xuan J, Fei J, 1Shanghai Centennial Scientific Ltd, Shanghai, China, 2Sun Yat-Sen University, Guangzhou, China, 3Ferring Pharmaceutical Consulting (Shanghai) Co., Ltd., Shanghai, China

4:00 - 4:15  
**CO2**  
Using QALYS vs DALYS to Measure Cost-Effectiveness: Does it Matter?  
Feng X, Ollendorf DA, Kim DD, Cohen JT, Neumann PJ, Tufts Medical Center, Boston, MA, USA

4:15 - 4:30  
**CO3**  
The Clinical and Economic Impact of HCV Treatment on Non-Hepatic Cancers Among HCV-Infected Patients  
Wang W, Lo Re III V, Guo Y, Xiao H, Brown J, 1University of Florida, College of Pharmacy, Gainesville, FL, USA, 2University of Pennsylvania, Philadelphia, PA, USA, 3University of Florida, College of Medicine, Gainesville, FL, USA, 4Bristol-Myers Squibb, Lawrenceville, NJ, USA

4:30 - 4:45  
**CO4**  
Alemtuzumab vs Generic Glatiramer Acetate 20mg in Patients with Relapsing Forms of Multiple Sclerosis: A Cost-Effectiveness Study in the United States  
Chirikov V, Ma I, Joshi N, Patel D, Smith A, Giambrone C, Cornelio N, Greene N, Hashemi L, 1Pharmerit International, Bethesda, MD, USA, 2Sanofi, Cambridge, MA, USA

**P12: Real-World Data Studies**  
Rooms 383-385 (3rd Floor)

3:45 - 4:00  
**RW1**  
The Impact of Delaying ALK Inhibitor Therapy on Outcomes: A Prescription Time Matching Method  
Sheinson D, Wu N, Wong W, 1Genentech, Inc., San Francisco, CA, USA, 2Genentech, Inc., South San Francisco, CA, USA

4:00 - 4:15  
**RW2**  
Retrospective Real-World Assessment of Response Outcomes in Oncology  
Espirito JL, Aguilar K, Boyd M, Frytak J, Robert NJ, 1McKesson Life Sciences, The Woodlands, TX, USA, 2McKesson Specialty Health, The Woodlands, TX, USA

4:15 - 4:30  
**RW3**  
Framework for Reliable Value Assessment of Treatments Using Causal Analysis of Observational Data: Support Matching Biological Therapy to Rheumatoid Arthritis Patients  
Shimoni Y, Ravid S, Bak P, Karavani E, Hensley Alford S, Meade D, Goldschmidt Y, 1IBM Research - Haifa, Tel Aviv, TA, Israel, 2IBM Research - Haifa, Givaatam, Israel, 3IBM Research - Haifa, Haifa, Haifa, Israel, 4IBM Watson Health, Cambridge, MA, USA

4:30 - 4:45  
**RW4**  
Development of Real-World Data and the Use of RWD for Evidence Generation in China  
Cai B, Xie Y, Gong Y, Luo W, Qu H, Liu J, 1IQVIA, Shanghai, China, 2IQVIA, Shanghai City, China

5:00PM - 6:00PM  
**BREAKOUT SESSION 7**

**IP19:** How Should Data on Social Determinants of Health be Best Used to Improve Health Outcomes and Reduce Disparities?  
Rooms 388-390 (3rd Floor)

Moderator: Christie Teigland, PhD, Avalere Health - An Inovalon Company, Bowie, MD, USA  
Panelists: Karl Kilgore, PhD, Avalere Health - An Inovalon Company, Bowie, MD, USA; Matthew Pickering, PharmD, Pharmacy Quality Alliance, Alexandria, VA, USA; Angela Hagan, MPA, PhD, Humana, Inc., Willowick, OH, USA

**IP20:** How is the “Regulatory-Grade” Criterion Defined and What Does It Take For RWE to Meet it?  
Rooms 278-282 (2nd Floor)

Moderator: David Thompson, PhD, Syneos Health, Manchester, MA, USA  
Panelists: Dan Riskin, MD, MBA, Verantos, San Francisco, CA, USA; William H Crown, PhD, OptumLabs, Cambridge, MA, USA; David Martin, MD, MPH, US Public Health Service; Center for Drug Evaluation and Research, Silver Spring, MD, USA

**W13:** Leveraging Patient-Provided Information to Improve Real-World Evidence: Getting to Good Practices on How  
Rooms 395-396 (3rd Floor)

Discussion Leaders: Elisabeth Oehrlein, PhD, MS, National Health Council, Washington, DC, USA; Richard J. Willke, PhD, ISPOR, Lawrenceville, NJ, USA; Cristina Masseria, MSc, PhD, Pfizer, New York, NY, USA; Chris L. Pashos, PhD, AbbVie US LLC, Chicago, IL, USA

**W14:** Multicriteria Decision Analysis for Healthcare Decision Making in the United States: Active Learning Through a Real-Time MCDA Case Study  
Rooms 393-394 (3rd Floor)

Discussion Leaders: R. Brett McQueen, PhD, University of Colorado Denver, Denver, CO, USA; Jonathan D Campbell, PhD, University of Colorado Denver, Aurora, CO, USA; Zoltan Kalo, PhD, Eötvös Loránd University, and Syreon Research Institute, Budapest, Hungary
Tuesday May 21

W15: Excel With Your Economic Models Using R  Room 386-387 (3rd Floor)
Discussion Leaders: Devin Incerti, PhD. Precision Health Economics, Oakland, CA, USA; Joseph Frank Levy, PhD. Johns Hopkins University, Baltimore, MD, USA; Jeroen P. Jansen, PhD. Innovation and Value Initiative, Los Angeles, CA, USA

P13: Oncology Studies  Rooms 383-385 (3rd Floor)
5:00 - 5:15  ON1  Understanding Variation in Treatment Sequences and Outcomes in Metastatic Colorectal Cancer: Using Real-World Data to Answer Real-World Questions
Wong HL1, Degeling K1, Jalali A1, Shapiro J1, Kosmider S1, Wong R1, Lee B1, Burge M1, Tie J1, Yip D1, Nott L1, Khattak A1, Lim S10, Caird S11, IJzerman M12, Gibbs P1, 1Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia, 2University of Twente, Enschede, Netherlands, 3Cabrini Health, Malvern, VIC, Australia, 4Western Health, Footscray, VIC, Australia, 5Walter and Eliza Hall Institute of Medical Research, Box Hill, Australia, 6Royal Brisbane and Women's Hospital, South Brisbane, QLD, Australia, 7The Canberra Hospital, Garran, ACT, Australia, 8Royal Hobart Hospital, Hobart, TAS, Australia, 9Flona Stanley Hospital, Murdoch, Australia, 10Campbelltown Hospital, Campbelltown, NSW, Australia, 11Gold Coast University Hospital, Southport, QLD, Australia, 12University of Melbourne, Melbourne, VIC, Australia

5:15 - 5:30  ON3  Impact of BRCA1/2 Mutation Status on Patient-Reported General Health Status in HER2-Advanced Breast Cancer: Results from a US Real-World Study
Niyazov A1, Lewis K1, Kemp J1, Rider A1, 1Pfizer Inc., New York, NY, USA, 2Adelphi Real World, Cheshire, UK

5:30 - 5:45  ON4  Review of the Application of Health-Related Quality of Life (HRQOL) Data in Recent Health Technology Assessments (HTAS) of Cancer Immunotherapies (IOS) By the National Institute for Health and Care Excellence (NICE)
Bullement A1, Shields G1, Hatsell AJ1, Schlichting M2, Bharmal M3, 1Delta Hat Limited, Nottingham, UK, 2University of Manchester, Manchester, UK, 3Merck KGaA, Darmstadt, Germany

P14: Neurological Disorders Studies  Room 292 (2nd Floor)
5:00 - 5:15  ND1  Experiences, Healthcare Needs, and Potential Patient-Centered Approaches to Treat Depression and Fatigue Among Individuals with Parkinson's Disease: A Focus Group Study
Bhattacharjee S1, Zhou L1, Yegezu Z1, Khalil M1, Sherman S1, 1University of Arizona, Tucson, AZ, USA, 2The University of Arizona, Tucson, AZ, USA, 3West Virginia University, New York, NY, USA, 4The University of Arizona, College of Medicine, Tucson, AZ, USA

5:15 - 5:30  ND2  Cost-Utility Analysis of Single Dose Gene-Replacement Therapy for Spinal Muscular Atrophy Type 1 Compared to Chronic Nusinersen Treatment
Malone D1, Dean R1, Miller B1, Arjunji R1, Feltner DE1, Sproule DM1, Jensen IS2, Maru B1, Dabbous O1, 1University of Arizona, Tucson, AZ, USA, 2Precision Xtract, Boston, MA, USA, 3AveXis, Inc., Bannockburn, IL, USA

5:30 - 5:45  ND3  Use of Group-Based Trajectory Modeling to Identify Adherence Clusters in Patients with Multiple Sclerosis Newly-Initiating Once- or Twice-Daily Oral Disease-Modifying Drugs
Nicholas J1, Edwards NC1, Edwards RA1, Dellarole A1, Manca L1, Harlow DE1, Phillips A1, 1OhioHealth Multiple Sclerosis Center, Columbus, OH, USA, 2Health Services Consulting Corporation, Boxborough, MA, USA, 3Fair Dynamics Consulting, Milan, Italy, 4EMD Serono, Inc., Rockland, MA, USA

5:45 - 6:00  ND4  Comparison of Trinetx Electronic Medical Record Database and National Ambulatory Medical Care Survey: Findings on the Inappropriate Medications Use in Parkinson's Disease in the United States
Masurkar P1, Rege S1, Aparasu RR1, 1College of Pharmacy, University of Houston, Houston, TX, USA, 2Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, TX, USA, 3University of Houston, Houston, TX, USA

5:00PM - 6:15PM  ISPOR FORUMS
ISPOR Women in HEOR Initiative: Mentors and Thought Leadership: Relationship Building for Career Success
Rooms 391-392 (3rd Floor)
This session is open to all attendees (women and men) interested in the advancement of women in the health economics and outcomes research (HEOR) field. The vision of the ISPOR Women in HEOR Initiative is to support the growth, development, and contribution of women in HEOR; to serve as a catalyst for women’s leadership in the field; and to offer a platform for ISPOR women to collaborate, network, share, and mentor each other. We will outline the initiative's work to date, including results from a needs assessment survey and expand on growth opportunities including mentorship and networking with colleagues who seek to advance women's leadership in HEOR.
Speakers: Renée Arnold, PharmD, RPh, Icahn School of Medicine at Mount Sinai, and ICON PLC, New York, NY, USA; Shelby Reed, PhD, RPh, Duke University, Durham, NC, USA
Tuesday May 21

6:00PM - 7:00PM  POSTER AUTHOR DISCUSSION HOUR – SESSION 4  Poster and Exhibit Hall, Hall H

6:00PM - 7:30PM  NETWORKING RECEPTION IN THE EXHIBIT HALL  Poster and Exhibit Hall, Hall H
After two full days of education sessions, learning opportunities, and scheduled meetings it is time to unwind and network! A New Orleans Jazz Quartet will provide the background music while you and your colleagues enjoy complimentary wine, beer, soft drinks and hors d'oeuvres. Take advantage of this dedicated time to visit the exhibitors you haven't had a chance to connect with, continue conversations with your colleagues, review posters, or just take advantage of the sponsored lounges to sit down, network and relax!

6:30PM - 7:30PM  ISPOR BOOTH EVENT  Poster and Exhibit Hall, Booth #407
Women in HEOR Networking Reception
Meet the speakers from the Women in HEOR open meeting and network with others who support the advancement of women in the field of HEOR.

Media Partners

ISPOR thanks its media partners, PM360 and The American Journal of Managed Care for their help in promoting the ISPOR 2019 conference to new audiences in the healthcare and health policy space.

For more information about our media partners, visit them online at www.pm360online.com and www.ajmc.com.

www.ispor.org
### Wednesday May 22

<table>
<thead>
<tr>
<th>7:00AM - 3:30PM</th>
<th><strong>COAT ROOM HOURS</strong> Hall H Lobby</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00AM - 2:00PM</td>
<td><strong>SPEAKER READY ROOM</strong> Room 277 (2nd Floor)</td>
</tr>
<tr>
<td>8:00AM - 3:00PM</td>
<td><strong>REGISTRATION HELP DESK HOURS</strong> Hall H Lobby</td>
</tr>
<tr>
<td>8:00AM - 3:00PM</td>
<td><strong>MULTI-FAITH PRAYER ROOM</strong> Room 298 (2nd Floor)</td>
</tr>
<tr>
<td>8:00AM - 3:00PM</td>
<td><strong>NURSING MOTHERS’ ROOM</strong> Room 299 (2nd Floor)</td>
</tr>
</tbody>
</table>
| 7:00AM - 8:15AM | **ISPOR FORUMS** Room 292 (2nd Floor)  
ISPOR Health Preference Methods Special Interest Group  
During the open meeting, participants will receive an update on the activities conducted by the SIG. These include the SIG business plan, the SIG member-engagement plan, and the new SIG project. |
| 7:15AM - 8:15AM | **EDUCATIONAL SYMPOSIUM** Rooms 278-282 (2nd Floor)  
The Evolution of HTAs: What Matters Most?  
*Sponsored by: Amgen*  
*Moderator: Anusha Kheir, MPH, Amgen, Thousand Oaks, CA, USA*  
*Speakers: Louis P. Garrison, PhD, University of Washington, Seattle, WA, USA; Felicity McNeill, PSM, Hepatitis Australia, Woden, ACT, Australia; Gordon G. Liu, PhD, Peking University, Beijing, China* |
| 8:30AM - 9:30AM | **BREAKOUT SESSION 8**  
**IP21: Replicable and Robust Database Evidence: What Does it Look like?** Rooms 278-282 (2nd Floor)  
*Moderator: Sebastian Schneeweiss, MD, ScD, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA*  
*Panelists: Shirley Wang, PhD, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Kristijan Kahler, RPh, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Laura Happe, PharmD, MPH, *Journal of Managed Care and Specialty Pharmacy*, Alexandria, VA, USA* |
| 8:00AM - 3:00PM | **ISPOR FORUMS** Room 292 (2nd Floor)  
*Moderator: Anita Burrell, BA, MA, MBA, EVERSANA, Flemington, NJ, USA*  
*Panelists: Chad Pettit, MBA, BSc, Amgen, Thousand Oaks, CA, USA; Ha Kung Wong, JD, MBA, Venable Fitzpatrick, New York, NY, USA; Joseph Franklin, PhD, JD, US Food and Drug Administration, Silver Spring, MD, USA* |
| 8:00AM - 3:00PM | **ISPOR FORUMS** Room 292 (2nd Floor)  
**IP23: Can an Alternative Evaluation Approach, Addressing the Needs of the Purchaser Rather Than the Payer, Be the Answer to Standardizing the Information Set Used to Make Healthcare Purchasing Decisions?** Rooms 393-394 (3rd Floor)  
*Moderator: Laura T. Pizzi, PharmD, MPH, RPh, Rutgers University, Piscataway, NJ, USA*  
*Panelists: Randy Vogenberg, PhD, Institute for Integrated Healthcare, Employer Provider Interface Council of the Hospital Quality Foundation, Greenville, SC, USA; Michael Bryan Pursel, BPharm, RPh, MBA, CHP, Sanofi, Morrison, CO, USA; Richard Bullard, BPharm, Pharmacy Benefit Management Consultant, Phoenix, AZ, USA* |
| 8:00AM - 3:00PM | **W16: Eliciting and Applying Patient Preference Information for Regulatory Decision-Making: What Have We Learned and Where Are We Going?** Rooms 395-396 (3rd Floor)  
*Discussion Leaders: Anindita Saha, BSE, US Food & Drug Administration, Silver Spring, MD, USA; Stephanie Christopher, MA, Medical Device Innovation Consortium, Arlington, VA, USA; Tonya Roney Moore, WomenHeart: The National Coalition for Women with Heart Disease, Burlington, NC, USA; Juan Marcos Gonzalez Sepulveda, PhD, Duke University, Durham, NC, USA* |
Wednesday  May 22

**P15: Cost and Resource Use Studies**  Rooms 383-385 (3rd Floor)

8:30 - 8:45

**CR1**  Patient Presentation, Complications and Health Resource Utilization Associated with Hardware Removal Within 1-Year After Open Reduction Internal Fixation of Femur Fractures

Chitnis AS1, Vanderkarr M2, Amolotia T1, Foley E1, Sparks C1, Holy CE1, 1Johnson & Johnson, New Brunswick, NJ, USA, 2DePuy Synthes, Inc., Raynham, MA, USA, 3Johnson & Johnson, Raynham, MA, USA, 4DePuy Synthes, West Chester, PA, USA

8:45 - 9:00

**CR2**  US National Payers Analysis of the Incremental Healthcare Burden Among Patients with Treatment-Resistant Depression

Shrestha A1, Goutam P1, Roach M1, Everson K1, Sison S1, Joshi K2, Sheehan JJ2, Heerlein K2, Jena AB3, 1Precision Health Economics, Los Angeles, CA, USA, 2Janssen Pharmaceuticals, Titusville, NJ, USA, 3Harvard Medical School, Boston, MA, USA

9:00 - 9:15

**CR3**  Therapy Choice and Cost of Care in Patients with Advanced or Recurrent Endometrial Cancer Previously Treated with Platinum-Based Therapy: Analysis of US Claims Data

Pothuri B1, Perhanidis J2, Gibson CJ2, Brown J1, 1New York University Langone Medical Center, NYU School of Medicine, New York, NY, USA, 2TESARO, Inc., Waltham, MA, USA, 3Levine Cancer Institute, Atrium Health, Charlotte, NC, USA

9:15 - 9:30

**CR4**  Resource Utilization within 30 Days of Car T Cells for Hematologic Malignancies


---

**P16: Treatment Patterns**  Rooms 386-387 (3rd Floor)

8:30 - 8:45

**TP1**  Real-World Treatment Patterns Among Patients with Metastatic Urothelial Cancer Receiving Second-Line Therapy in the US Veteran Population

Bhanegaonkar A1, Kim R1, Pandya S1, Krulwich S1, Wang L1, Pennock G1, Phatak H1, 1EMD Serono, Inc., Rockland, MA, USA, 2Pfizer, Inc., New York, NY, USA, 3STATinMED Research, Pano, TX, USA, 4Pfizer, Inc., Collegeville, PA, USA

8:45 - 9:00

**TP2**  Community Rheumatologists’ Experience and Views on Non-Medical Switching to Biosimilars

Klink A1, Ye H1, Jeune-Smith Y1, Phillips Jr EG2, Feinberg BA2, 1Cardinal Health Specialty Solutions, Philadelphia, PA, USA, 2Cardinal Health Specialty Solutions, Dublin, OH, USA

9:00 - 9:15

**TP3**  Factors Associated with Prescribing of Oral Disease Modifying Agents in Multiple Sclerosis

Earla JR1, Hutton GJ2, Thornton JD1, Aparasu RR1, 1University of Houston, Houston, TX, USA, 2Baylor College of Medicine Medical Center, McNair Campus, Houston, TX, USA

9:15 - 9:30

**TP4**  Real-World Treatment Patterns for Patients with Metastatic Head and Neck Squamous Cell Carcinoma (MHNSCC) Treated with Immuno-Oncology (IO) Therapy

Huang H1, Shenolikar R2, Seal B2, Tse J1, Burudpakdee C1, 1IQVIA, Cambridge, MA, USA, 2AstraZeneca, Gaithersburg, MD, USA, 3IQVIA, Fairfax, VA, USA

---

**P17: Conceptual Papers**  Rooms 391-392 (3rd Floor)

8:30 - 8:45

**CP1**  It is All Relative! Impact of the Institute for Clinical and Economic Review (ICER) Budget Impact Threshold on Pricing Considerations

Liu S1, Migliaccio-Walle K1, Brown D1, 1Xcenda, LLC, Palm Harbor, FL, USA, 2Xcenda, Palm Harbor, FL, USA

8:45 - 9:00

**CP2**  Estimating the Survival and Cost Impact of Introducing First-Line Alectinib and Osimertinib for Patients with Advanced NSCLC: An Iten Model Assessment

Moldaver D1, Zhou A1, Grima D1, Hurry M1, 1Cornerstone Research Group, Burlington, ON, Canada, 2AstraZeneca Canada, Mississauga, ON, Canada

9:00 - 9:15

**CP3**  Eliciting Value Elements for a Patient-Driven Value Assessment

Hong Y1, Zhang C, Slezko JF, dosReis S, University of Maryland School of Pharmacy, Baltimore, MD, USA

9:15 - 9:30

**CP4**  Payer Perspectives on Patient Reported Outcomes Measures for Reimbursement Decision-Making in the United States

Mesana L1, Dubois de Gennes C1, Syed IA1, 1Amaris, Jersey City, NJ, USA, 2Amaris, Levallois-Perret, France, 3Amaris, Toronto, ON, Canada

---

9:30AM - 2:00PM  POSTER & EXHIBIT HALL HOURS  Poster and Exhibit Hall, Hall H
### Wednesday May 22

**9:30AM - 2:00PM** RESEARCH POSTER PRESENTATIONS – SESSION 5 Poster and Exhibit Hall, Hall H

**9:45AM - 10:45AM** PhRMA FOUNDATION SESSION/AWARDS Room 386-387 (3rd Floor)

This session will highlight the efforts of the four PhRMA Foundation Value Assessment Centers of Excellence and the new and diverse approaches they are using to capture and measure value. At the conclusion of this session, the Foundation will present their 2019 awards in Health Outcomes and Value Assessment to recognize the award recipients and promote these two areas of support of young scientists and research efforts.

**Moderator:** Sachin Kamal-Bahl, PhD, SKB Consulting Inc., Philadelphia, PA, USA

**Speakers:**
- Susan dos Reis, PhD, University of Maryland School of Pharmacy, Baltimore, MD, USA
- George Miller, PhD, Altarum, Ann Arbor, MI, USA
- Jonathan D. Campbell, PhD, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA
- Peter J. Neumann, ScD, Tufts Medical Center, Boston, MA, USA

**9:45AM - 10:45AM** BREAKOUT SESSION 9

**IP24: Can Meaningful Models Be Constructed for Rare Conditions?** Rooms 278-282 (2nd Floor)

**Moderator:** C. Daniel Malone, PhD, RPh, University of Arizona, Tucson, AZ, USA

**Panelists:**
- Richard Chapman, PhD, MS, Institute for Clinical and Economic Review, Boston, MA, USA
- Omar Dabbous, MD, US Food and Drug Administration, Silver Spring, MD, USA
- Andrew Tackett, MHA, MPH, Surgical, Sunnyvale, CA, USA
- Scott Tackett, MHA, MPH, Surgical, Sunnyvale, CA, USA
- Somesh Nigam, PhD, Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA

**IP25: Is There an Urgent Need to Explore the Opportunities and Challenges of Wide Use of RWE in Medical Devices?** Rooms 391-392 (3rd Floor)

**Moderator:** Lizheng Shi, PhD, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA

**Panelists:**
- Dongyi (Tony) Du, MD, PhD, US Food and Drug Administration, Silver Spring, MD, USA
- Scott Tackett, MHA, MPH, Surgical, Sunnyvale, CA, USA
- Somesh Nigam, PhD, Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA

**IP26: Could Formal HTA Be the Solution to High Healthcare Costs in the USA?** Rooms 393-394 (3rd Floor)

**Moderator:** Wrik Ghosh, BA, MSc, Costello Medical Singapore Pte Ltd, Singapore, Singapore

**Panelists:**
- Daniel A. Ollendorf, PhD, Tufts Medical Center, Boston, MA, USA
- Thomas Butt, PhD, Peking University, Beijing, China
- Sarah Breen, MA, MSc, MSD UK, Hoddesdon, UK

**W18: Generating External Control Arms Using Real-World Data: Analytic Challenges and Recommendations** Rooms 395-396 (3rd Floor)

**Discussion Leaders:**
- Carrie Savage Bennette, PhD, MPH, Flatiron, Seattle, WA, USA
- Blythe Adamson, PhD, MPH, Flatiron Health, New York, NY, USA
- Anirban Basu, PhD, University of Washington, Seattle, WA, USA

**W19: Health Economists Can Help Reduce the Uncertainty of the Risk in Value-Based Contracts!** Rooms 388-390 (3rd Floor)

**Discussion Leaders:**
- Anju Parthan, PhD, Alkermes, Inc., Waltham, MA, USA
- Morgan Kruse, BA, Optum, San Jose, CA, USA
- Kelly Fust, MS, Optum, Plymouth, MA, USA
- Michele Kohli, PhD, Quadrant Health Economics, Inc., Hamilton, ON, Canada

**P18: Diabetes Studies** Rooms 383-385 (3rd Floor)

<table>
<thead>
<tr>
<th>9:45 - 10:00</th>
<th>DM1 Disparities in the Quality of Care for Diabetes Among US Adults: The National Health and Nutrition Examination Survey (NHANES), 1999 to 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Kamat S1, Muzumdar J1, Gousse Y2, Gu A3, 1St. John’s University, Queens, NY, USA, 2College of Pharmacy and Health Sciences, St. John’s University, Jamaica, NY, USA, 3College of Pharmacy and Health Sciences, St. John’s University, New York, NY, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:00 - 10:15</th>
<th>DM2 Adherence to DPP-4 Inhibitors vs Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gor D1, Lee TA1, Schumock G2, Walton SM2, Gerber B3, Nutescu EA, Touchette D1, 1University of Illinois at Chicago, Chicago, IL, USA, 2University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA, 3Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 4University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:15 - 10:30</th>
<th>DM3 Quantifying the Opportunity to Reduce Total Cost of Care through Targeted Medication Prioritization and Adherence Improvement in Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Schneeweiss S1, Eapen S2, Jan S1, 1Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA, 2Aetion, Inc, Boston, MA, USA, 3Horizon Blue Cross Blue Shield, Newark, NJ, USA</td>
</tr>
</tbody>
</table>
Wednesday May 22

10:30 - 10:45 **DM4**  Modeling the Incidence of Microvascular Complications at Glycemic Control Targets Recommended by the American Diabetes Association for Adult Patients with Type 1 Diabetes: An Analysis Using the Prime Diabetes Model
Pollock R¹, Valentine WJ², ¹Covalence Research Ltd, London, UK, ²Ossian Health Economics and Communications GmbH, Basel, Switzerland

10:00AM - 11:00AM **ISPOR BOOTH EVENT**  Poster and Exhibit Hall, Booth #407
Take Control of Your ISPOR Experience: Update Your Member Profile and Email Preferences

11:00AM - 12:30PM **WELCOME & THIRD PLENARY SESSION**  New Orleans Theater, Mid-Level Entrance
Welcome From ISPOR President and ISPOR 2020 Conference Announcement
Federo Augustovski, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina

**THIRD PLENARY SESSION: IS AFFORDABILITY DRIVING A NEED TO REVOLUTIONIZE DRUG PRICING?**
Moderator: Colleen M. Flood, University of Ottawa Centre for Health Law, Policy, and Ethics, Ottawa, ON, Canada
Speakers: Muna Bhanji, RPh, Merck, Philadelphia, PA, USA; Meindert Boysen, PharmD, MSc. NICE, Manchester, England; John M. O’Brien, PharmD, MPH, US Department of Health and Human Services, Washington, DC, USA; Mark Trusheim, MS, NEWDIGS and MIT, Boston, MA, USA

12:30PM - 1:45PM  **EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION 5**  Poster and Exhibit Hall, Hall H

12:30PM – 2:00PM  **LUNCH IN THE POSTER & EXHIBIT HALL**  Poster and Exhibit Hall, Hall H

12:45PM - 1:45PM  **POSTER AUTHOR DISCUSSION HOUR – SESSION 5**  Poster and Exhibit Hall, Hall H

2:00PM - 3:00PM  **BREAKOUT SESSION 10**

**W20: Improving Patient Access to Life-Saving Therapies: What Needs to Be Done to Fulfill the Promise of Biosimilars**  Rooms 391-392 (3rd Floor)
Discussion Leaders: Steven Simoens, MSc, PhD, KU Leuven, Leuven, Belgium; Cate Lockhart, PharmD, PhD, Biologics and Biosimilars Collective Intelligence Consortium, Greenbank, WA; Jacqueline Vanderpuye-Orgle, PhD, PAREXEL, Glendale, CA, USA; Delphine Courmier, PharmD, MBA, AMGEN, Thousand Oaks, CA, USA

**W21: Identifying and Addressing Barriers to the Adoption of Standardized Outcome Measures in Patient Registries and Clinical Practice**  Rooms 393-394 (3rd Floor)
Discussion Leaders: Richard Gliklich, MD, OM1, Boston, MA, USA; Elise Berliner, PhD, Agency for Healthcare Research and Quality, Rockville, MD, USA

**W22: Beyond Trial Replication: Using Real-World Data to Bridge the Efficacy-Effectiveness Gap in Healthcare**  Rooms 395-396 (3rd Floor)
Discussion Leaders: David Thompson, PhD, Syneos Health, Manchester, MA, USA; Manfred Stapff, MD, PhD, TriNetX Inc., Cambridge, MA, USA; Joseph Dicesare, MPH, Allergan, Madison, NJ, USA

**W23: Getting the Most Out of Value-Based Contracting for Medical Devices**  Rooms 388-390 (3rd Floor)
Discussion Leaders: Jyoti Aggarwal, MHS, Pharrmerit International, Bethesda, MD, USA; Vasudha Bal, MSc, MBA, BD, Franklin Lakes, NJ, USA; Trevor Wear, JD, MHA, Silday Austin LLP, Chicago, IL, USA; Dale Cooke, MA, JD, PhillyCooke Consulting, Penn Valley, PA, USA

**W24: Patient-Focused Drug Development: Operational Considerations for Conducting Qualitative Research in Special Populations**  Rooms 383-395 (3rd Floor)
Discussion Leaders: Elizabeth (Nicki) Bush, MHS, Eli Lilly and Company, Indianapolis, IN, USA; Selena Daniels, PharmD, MS, US Food and Drug Administration, Silver Spring, MD, USA; Shannon Keith, MS, Clinical Outcomes Solutions, Chicago, IL, USA; Kim Kelly, PhD, Clinical Outcomes Solutions, Tucson, AZ, USA
**Good Practices for Outcomes Research**

- Setting international standards with consensus guidance recommendations
- Recognized with a “Power of A” Award that acknowledges innovative, effective, and broad-reaching programs that positively impact the world

---

**Tell Us What You Think**

**ISPOR Conference Evaluation**

*We’re listening.*

Please complete a simple online evaluation after the conference to help us plan for future conferences.

It’s simple—answer a few multiple-choice questions by Friday, June 7, 2019, using the ISPOR conference app or on the ISPOR website at www.ispor.org.

*Be a voice and help us plan for 2019.*

**ISPOR Session Evaluation**

*Have thoughts about a particular session? We’re interested.*

- Evaluate presentations through the ISPOR conference app
- Provide real-time responses immediately following the presentation
- 2-question evaluation for each presentation that can be accessed through the description portion of the presentation on the app.
## Invitational Group Meetings

Many ISPOR Member Groups meet in person during the conference to work on projects, reports, articles and other specific tasks that advance their group's objectives. These member groups include: Special Interest Groups (SIGs), Task Forces (TF), Councils & Roundtables, Consortium, Networks, and Chapters. **Invitational Group Meetings are by invitation only.**

Participants will receive an email reminder and notification of any changes to the group meeting schedule from the ISPOR Staff or ISPOR member coordinating the meeting. Invitational Group Meetings are included in the conference app daily schedule to allow invited participants the option to add the meeting to their personal schedule.

Visit [www.ispor.org](http://www.ispor.org) >>Member Groups for information on how to join the many member groups.

### Sunday, May 19

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30AM - 5:30PM</td>
<td>ISPOR Health Technology Assessment - Pharmacy &amp; Therapeutics (HTA-P&amp;T) Roundtable - North America</td>
<td>Room 291 (2nd Floor)</td>
</tr>
<tr>
<td>12:00PM - 1:00PM</td>
<td>ISPOR Joint Councils Luncheon</td>
<td>Room 289 (2nd Floor)</td>
</tr>
<tr>
<td>1:00PM - 4:00PM</td>
<td>ISPOR Institutional Council Roundtable</td>
<td>Room 288 (2nd Floor)</td>
</tr>
<tr>
<td>1:00PM - 4:00PM</td>
<td>ISPOR Student Network Leadership Retreat</td>
<td>Room 397 (3rd Floor)</td>
</tr>
<tr>
<td>2:30PM - 3:30PM</td>
<td>ISPOR Publications Management Advisory Board (MAB)/ISPOR Journal Editors-in-Chief Joint Business Meeting</td>
<td>Room 398 (3rd Floor)</td>
</tr>
</tbody>
</table>

### Monday, May 20

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00AM - 8:15AM</td>
<td>ISPOR Machine Learning Task Force Proposal Group</td>
<td>Room 399 (3rd Floor)</td>
</tr>
<tr>
<td>7:15AM - 8:15AM</td>
<td>ISPOR Statistical Methods Special Interest Group</td>
<td>Room 297 (2nd Floor)</td>
</tr>
<tr>
<td>7:15AM - 8:15AM</td>
<td>ISPOR Value &amp; Outcomes Spotlight Editorial Advisory Board</td>
<td>Room 288 (2nd Floor)</td>
</tr>
<tr>
<td>7:15AM - 8:15AM</td>
<td>ISPOR Health Preference Methods Special Interest Group</td>
<td>Room 398 (3rd Floor)</td>
</tr>
<tr>
<td>7:15AM - 8:15AM</td>
<td>ISPOR Oncology Special Interest Group</td>
<td>Room 289 (2nd Floor)</td>
</tr>
<tr>
<td>7:15AM - 8:15AM</td>
<td>ISPOR Biosimilar Special Interest Group</td>
<td>Room 290 (2nd Floor)</td>
</tr>
<tr>
<td>11:00AM - 12:30PM</td>
<td>ISPOR Patient Preference Measurement Task Force Proposal Group</td>
<td>Room 398 (3rd Floor)</td>
</tr>
<tr>
<td>11:00AM - 12:15PM</td>
<td>ISPOR Medical Devices and Diagnostics Special Interest Group</td>
<td>Room 297 (2nd Floor)</td>
</tr>
<tr>
<td>12:00PM - 1:00PM</td>
<td>ISPOR CEE Consortium</td>
<td>Room 289 (2nd Floor)</td>
</tr>
<tr>
<td>12:15PM - 4:45PM</td>
<td>ISPOR Patient Representatives Roundtable - North America</td>
<td>Room 291 (2nd Floor)</td>
</tr>
<tr>
<td>1:00PM - 2:00PM</td>
<td>ISPOR Midwest Chapter</td>
<td>Room 288 (2nd Floor)</td>
</tr>
<tr>
<td>1:00PM - 2:00PM</td>
<td>ISPOR Africa Network</td>
<td>Room 289 (2nd Floor)</td>
</tr>
<tr>
<td>1:00PM - 2:00PM</td>
<td>ISPOR Asia Consortium Industry Committee</td>
<td>Room 290 (2nd Floor)</td>
</tr>
<tr>
<td>4:00PM - 5:00PM</td>
<td>ISPOR Past Presidents Council</td>
<td>Room 288 (2nd Floor)</td>
</tr>
<tr>
<td>5:00PM - 7:00PM</td>
<td>ISPOR International Initiatives on the Assessment of the Value of Medical Technologies Working Group</td>
<td>Room 398 (3rd Floor)</td>
</tr>
<tr>
<td>5:15PM - 7:15PM</td>
<td>ISPOR Chapter Leadership Training</td>
<td>Room 397 (3rd Floor)</td>
</tr>
<tr>
<td>7:30PM - 9:00PM</td>
<td>ISPOR Value in Health Editorial Board and Editorial Advisory Board</td>
<td>Room 290 (2nd Floor)</td>
</tr>
</tbody>
</table>
## Invitational Group Meetings

### Tuesday, May 21

<table>
<thead>
<tr>
<th>Time</th>
<th>Group</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15AM - 8:15AM</td>
<td>ISPOR Open Source Models Special Interest Group</td>
<td>Room 399 (3rd Floor)</td>
</tr>
<tr>
<td>7:15AM - 8:15AM</td>
<td>ISPOR Patient Centered Special Interest Group</td>
<td>Room 398 (3rd Floor)</td>
</tr>
<tr>
<td>7:15AM - 8:15AM</td>
<td>ISPOR Clinical Outcomes Assessment Special Interest Group</td>
<td>Room 297 (2nd Floor)</td>
</tr>
<tr>
<td>11:00AM - 12:00PM</td>
<td>ISPOR Open Source Models Task Force</td>
<td>Room 399 (3rd Floor)</td>
</tr>
<tr>
<td>12:00PM - 1:00PM</td>
<td>ISPOR Colombia Chapter</td>
<td>Room 398 (3rd Floor)</td>
</tr>
<tr>
<td>12:00PM - 1:00PM</td>
<td>ISPOR Arabic Network</td>
<td>Room 289 (2nd Floor)</td>
</tr>
<tr>
<td>12:00PM - 2:00PM</td>
<td>ISPOR Student and Faculty Luncheon</td>
<td>Room 397 (3rd Floor)</td>
</tr>
<tr>
<td>2:00PM - 3:30PM</td>
<td>ISPOR Education Council</td>
<td>Room 290 (2nd Floor)</td>
</tr>
<tr>
<td>3:30PM - 4:30PM</td>
<td>ISPOR Student Roundtable</td>
<td>Room 397 (3rd Floor)</td>
</tr>
<tr>
<td>3:45PM - 4:45PM</td>
<td>ISPOR Value in Health Regional Issues Editorial Board &amp; Editorial Advisory Board</td>
<td>Room 398 (3rd Floor)</td>
</tr>
<tr>
<td>3:45PM - 5:15PM</td>
<td>ISPOR Performance Based Outcomes (PerFO) Task Force</td>
<td>Room 399 (3rd Floor)</td>
</tr>
<tr>
<td>7:00PM - 8:30PM</td>
<td>ISPOR Health Technology Assessment (HTA) Council</td>
<td>Room 290 (2nd Floor)</td>
</tr>
</tbody>
</table>

### Wednesday, May 22

<table>
<thead>
<tr>
<th>Time</th>
<th>Group</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15AM - 8:15AM</td>
<td>ISPOR Personalized/Precision Medicine Special Interest Group</td>
<td>Room 399 (3rd Floor)</td>
</tr>
<tr>
<td>7:15AM - 8:15AM</td>
<td>ISPOR Real-World Evidence Special Interest Group</td>
<td>Room 288 (2nd Floor)</td>
</tr>
<tr>
<td>7:15AM - 8:15AM</td>
<td>ISPOR Digital Health Special Interest Group</td>
<td>Room 398 (3rd Floor)</td>
</tr>
<tr>
<td>9:00AM - 10:00AM</td>
<td>ISPOR Boston Chapter</td>
<td>Room 397 (3rd Floor)</td>
</tr>
</tbody>
</table>
Benefits of Membership

Become a member of the global HEOR community:

• World-class, global scientific conferences
• MEDLINE®-indexed publications
• Knowledge products and online tools
• Educational and training programs
• Awards and recognition
• Career development

www.ispor.org/membership
NEW! ISPOR 2019 Exhibitor HEOR Theater*

Continue your education at the ISPOR 2019 Exhibitor HEOR Theater!
Be sure to make time in your conference schedule to attend these 30-minute insightful, informative, and educational sessions presented by ISPOR 2019 Exhibiting Companies. Exhibitor HEOR Theater is located in the Exhibit Hall.

MONDAY, MAY 20
11:15AM - 11:45AM
Getting to the “Why”: Gaining Additional Insights for HEOR Studies Through Diagnostic Laboratory Data
Presenters: Heather von Allmen, General Manager, Explorer Product, Prognos; Mohdhar Habib, Director, Global Health Economics, Amgen

2:30PM - 3:00PM
Demonstrating the Use of Constrained Optimization on A Real-World Problem
Presenters: Katherine A. Hicks, MS, Director of Health Economics, RTI Health Solutions (RTI-HS), Durham, NC, USA; Stephanie R. Earnshaw, PhD, Vice President of Health Economics, RTI Health Solutions (RTI-HS), Durham, NC, USA

RTI Health Solutions®

TUESDAY, MAY 21
11:15AM - 11:45AM
Integrated Research – A New Operating Model to Enable Research and Real-World Data as a Natural Output of Clinical Practice
Presenters: Stephanie Reisinger, Vice President, General Manager Veradigm Life Sciences

2:30PM - 3:00PM
Linked Data Breakthrough Delivers Major Advancement for PRO and Clinical Research
Presenters: Lulu K. Lee, PhD, Vice President, Health Outcomes Research, Kantar; Tom Haskell, Global Head of Data Analytics, Kantar

KANTAR

4:00PM - 4:30PM
Making the Patient Voice Count – Demonstrating When, Why, and How to Engage Patients
Presenters: Caitlyn Solen, PhD, Executive Director, Patient-Centered Outcomes Pharmerit International; Kelly McCarrier, PhD, MPH, Director and Qualitative Research Lead, Patient-Centered Outcomes Pharmerit International

*The HEOR Theater presentations are not an official educational offering of ISPOR 2019, and are not sponsored, endorsed or accredited by ISPOR.
More than 1700 poster presentations will be on display during the conference in the Poster & Exhibit Hall H (1st fl).

- The poster hall is organized in rows (A-N) and each poster board is numbered accordingly (e.g., A1, L15). Each poster has been assigned a specific numbered board location.
- Poster presentations also are available on the myISPOR2019.zerista.com web platform and mobile app.
- Presenting authors will be with their posters during the Poster Author Discussion Hour.
- An author index will be available in *Value in Health* (Volume 22, Suppl 1). The issue will be ONLINE ONLY, available 1 month after the meeting.

### Poster Presentations Display Hours

<table>
<thead>
<tr>
<th>POSTER PRESENTATION SESSIONS</th>
<th>POSTER LOCATION</th>
<th>PRESENTER SET-UP TIME</th>
<th>POSTER DISPLAY HOURS</th>
<th>AUTHOR DISCUSSION HOUR</th>
<th>PRESENTER DISMANTLE TIME*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SESSION 1: MONDAY, MAY 20</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCN: CANCER</td>
<td>Rows: A-K</td>
<td>8:00AM – 10:30AM</td>
<td>10:30AM – 2:00PM</td>
<td>1:00PM – 2:00PM</td>
<td>2:00PM</td>
</tr>
<tr>
<td>PGI: GASTROINTESTINAL DISORDERS</td>
<td>Rows: K</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PIT: INJURY &amp; TRAUMA</td>
<td>Rows: L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PVM: VETERINARY MEDICINE</td>
<td>Rows: L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION 2: MONDAY, MAY 20</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDB: DIABETES/ENDOCRINE/METABOLIC DISORDERS</td>
<td>Rows: A-E</td>
<td>3:00PM – 3:30PM</td>
<td>3:30PM – 7:00PM</td>
<td>6:00PM – 7:00PM</td>
<td>7:00PM</td>
</tr>
<tr>
<td>PIH: INDIVIDUAL'S HEALTH</td>
<td>Rows: E-G</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMH: MENTAL HEALTH</td>
<td>Rows: G-I</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMS: MUSCULOSKELETAL DISORDERS</td>
<td>Rows: I-K</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSU: SURGERY</td>
<td>Rows: K-L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION 3: TUESDAY, MAY 21</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAM: ALTERNATIVE MEDICINE &amp; NUTRITION</td>
<td>Rows: A</td>
<td>8:00AM – 10:30AM</td>
<td>10:30AM – 2:00PM</td>
<td>1:00PM – 2:00PM</td>
<td>2:00PM</td>
</tr>
<tr>
<td>PBI: BIOLOGICS/BIOSIMILARS/REGENERATIVE MEDICINE</td>
<td>Rows: A-B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCV: CARDIOVASCULAR DISORDERS</td>
<td>Rows: B-F</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PIN: INFECTIOUS DISEASES</td>
<td>Rows: F-I</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PND: NEUROLOGICAL DISORDERS</td>
<td>Rows: I-L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION 4: TUESDAY, MAY 21</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDG: DRUGS &amp; GENERICS</td>
<td>Rows: A-D</td>
<td>3:00PM – 3:30PM</td>
<td>3:30PM – 7:00PM</td>
<td>6:00PM – 7:00PM</td>
<td>7:00PM</td>
</tr>
<tr>
<td>PMU: MULTIPLE DISEASES</td>
<td>Rows: D-G</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRO: RARE &amp; ORPHAN DISEASES</td>
<td>Rows: G-I</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRS: RESPIRATORY-RELATED DISORDERS</td>
<td>Rows: I-L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PUK: URINARY/KIDNEY DISORDERS</td>
<td>Rows: L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION 5: WEDNESDAY, MAY 22</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PMD: MEDICAL DEVICES</td>
<td>Rows: A-B</td>
<td>8:00AM – 9:30AM</td>
<td>9:30AM – 2:00PM</td>
<td>12:45PM – 1:45PM</td>
<td>2:00PM</td>
</tr>
<tr>
<td>PNS: NO SPECIFIC DISEASE</td>
<td>Rows: B-J</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPM: PERSONALIZED &amp; PRECISION MEDICINE</td>
<td>Rows: J-K</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSS: SENSORY SYSTEM DISORDERS</td>
<td>Rows: K</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSY: SYSTEMIC DISORDERS/CONDITIONS</td>
<td>Rows: K-L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Posters that are not removed at the scheduled dismantle times will be discarded.*
Exhibit Program Overview

Exhibit Viewing Hours (Hall H)

Monday, May 20  10:30AM - 7:30PM (Welcome Reception 6:00PM - 7:30PM)
Tuesday, May 21  10:30AM - 7:30PM (Networking Reception 6:00PM - 7:30PM)
Wednesday, May 22  9:30AM - 2:00PM

Exhibitor HEOR Theater Hours (Hall H)

Monday, May 20
11:15AM - 11:45AM  Prognos
2:30PM - 3:00PM  RTI
4:00PM - 4:30PM  Precision Health Economics - Precision Xtract

Tuesday, May 21
11:15AM - 11:45AM  Veradigm Health
2:30PM - 3:00PM  Kantar
4:00PM - 4:30PM  Pharmerit

Networking and Lounges

Charging Lounge  Provided by EVERSANA, Johnson & Johnson, Veradigm Health, Poster & Exhibit Hall
Wi-Fi  Network: ISPOR2019  Password: HEALTHCORE  Sponsored by HealthCore

Sunday, May 19
8:00AM - 11:59PM  Exhibitor Set-Up (No re-entry after 10:00PM)

Monday, May 20
7:00AM - 10:30AM  Exhibitor Set-Up
10:30AM - 7:30PM  Exhibits Viewing
10:30AM - 11:00AM  Coffee Break & Exhibits Viewing
12:00PM - 1:30PM  Lunch
12:00PM - 1:30PM  Exhibits & Research Poster Presentations Viewing
3:15PM - 3:45PM  Coffee Break & Exhibits Viewing
6:00PM - 7:30PM  Welcome Reception Sponsored by Evidera

Tuesday, May 21
10:30AM - 7:30PM  Exhibits Viewing
10:30AM - 11:00AM  Coffee Break & Exhibits Viewing
12:00PM - 1:30PM  Lunch
12:00PM - 2:00PM  Exhibits & Research Poster Presentations Viewing
3:15PM - 3:45PM  Coffee Break & Exhibits Viewing
6:00PM - 7:30PM  Networking Reception Provided by ISPOR

Wednesday, May 22
9:30AM - 2:00PM  Exhibits Viewing
9:30AM - 10:00AM  Coffee Break & Exhibits Viewing
12:30PM - 2:00PM  Exhibits & Research Poster Presentations Viewing
12:30PM - 2:00PM  Lunch
2:00PM - 10:00PM  Exhibitor Dismantle
## Exhibitor Listing

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adelphi Real World &amp; Adelphi Values</td>
<td>201</td>
</tr>
<tr>
<td>Aetion</td>
<td>803</td>
</tr>
<tr>
<td>Amaris Consulting UK Ltd</td>
<td>902</td>
</tr>
<tr>
<td>AMPLEXOR</td>
<td>1004</td>
</tr>
<tr>
<td>Analysis Group</td>
<td>405</td>
</tr>
<tr>
<td>AplusA</td>
<td>1007</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>1012</td>
</tr>
<tr>
<td>Barrington James</td>
<td>1009</td>
</tr>
<tr>
<td>Black Swan Analysis Ltd</td>
<td>413</td>
</tr>
<tr>
<td>BHE</td>
<td>203</td>
</tr>
<tr>
<td>Boston Strategic Partners, Inc</td>
<td>308</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>702</td>
</tr>
<tr>
<td>Cardinal Health</td>
<td>809</td>
</tr>
<tr>
<td>CERToRs Consulting, LLC</td>
<td>Table 5</td>
</tr>
<tr>
<td>Certara Evidence &amp; Access*</td>
<td>300</td>
</tr>
<tr>
<td>Clinakos Inc</td>
<td>514</td>
</tr>
<tr>
<td>Clinical Practice Research Datalink (CPRD)</td>
<td>914</td>
</tr>
<tr>
<td>CHEORS</td>
<td>509</td>
</tr>
<tr>
<td>Cornerstone Research Group Inc</td>
<td>907</td>
</tr>
<tr>
<td>Costello Medical</td>
<td>310</td>
</tr>
<tr>
<td>Creativ-Ceutical</td>
<td>410</td>
</tr>
<tr>
<td>CTI Clinical Trial &amp; Consulting Services</td>
<td>903</td>
</tr>
<tr>
<td>Currant</td>
<td>Table 6</td>
</tr>
<tr>
<td>Datacubed Health</td>
<td>908</td>
</tr>
<tr>
<td>Decision Resources Group</td>
<td>1002</td>
</tr>
<tr>
<td>Digital Health Outcomes</td>
<td>821</td>
</tr>
<tr>
<td>Dymaxium, Inc</td>
<td>609</td>
</tr>
<tr>
<td>eMAX Health Systems, LLC</td>
<td>402</td>
</tr>
<tr>
<td>EPI-Q, Inc</td>
<td>213</td>
</tr>
<tr>
<td>Evaluserve</td>
<td>705</td>
</tr>
<tr>
<td>Evidence Partners</td>
<td>411</td>
</tr>
<tr>
<td>Evidera*</td>
<td>503</td>
</tr>
<tr>
<td>Exponent</td>
<td>811</td>
</tr>
<tr>
<td>FACT.org/FACITrans</td>
<td>303</td>
</tr>
<tr>
<td>FIECON</td>
<td>603</td>
</tr>
<tr>
<td>Future Science Group</td>
<td>211</td>
</tr>
<tr>
<td>Genesis Research</td>
<td>1011</td>
</tr>
<tr>
<td>HealthCore, Inc*</td>
<td>401</td>
</tr>
<tr>
<td>Huron</td>
<td>706</td>
</tr>
<tr>
<td>IBM Watson Health</td>
<td>911</td>
</tr>
<tr>
<td>ICON</td>
<td>1001</td>
</tr>
<tr>
<td>Ipsos HealthCare</td>
<td>409</td>
</tr>
<tr>
<td>IQVIA</td>
<td>505</td>
</tr>
<tr>
<td>ISPOR</td>
<td>407</td>
</tr>
<tr>
<td>JMDC Inc</td>
<td>415</td>
</tr>
<tr>
<td>Journal of Health Economics and Outcomes Research</td>
<td>Table 7</td>
</tr>
<tr>
<td>Kantar*</td>
<td>900</td>
</tr>
<tr>
<td>KMK Consulting, Inc</td>
<td>406</td>
</tr>
<tr>
<td>Lighthouse Outcomes</td>
<td>703</td>
</tr>
<tr>
<td>Mapi Research Trust</td>
<td>1005</td>
</tr>
<tr>
<td>Market Access Transformation</td>
<td>605</td>
</tr>
<tr>
<td>Mckesson</td>
<td>502</td>
</tr>
<tr>
<td>Monument Analytics</td>
<td>205</td>
</tr>
<tr>
<td>Normin Health Consulting</td>
<td>Table 8</td>
</tr>
<tr>
<td>Northwestern University</td>
<td>Table 9</td>
</tr>
<tr>
<td>Novosys Health</td>
<td>215</td>
</tr>
<tr>
<td>OM1</td>
<td>306</td>
</tr>
<tr>
<td>OPEN VIE</td>
<td>512</td>
</tr>
<tr>
<td>Optum</td>
<td>815</td>
</tr>
<tr>
<td>PAREXEL</td>
<td>905</td>
</tr>
<tr>
<td>Pharmerit International*</td>
<td>801</td>
</tr>
<tr>
<td>Policy Analysis, Inc</td>
<td>209</td>
</tr>
<tr>
<td>PRA Health Sciences</td>
<td>807</td>
</tr>
<tr>
<td>Precision Xtract/Precision Health Economics*</td>
<td>611</td>
</tr>
<tr>
<td>Premier</td>
<td>817</td>
</tr>
<tr>
<td>PRMA Consulting</td>
<td>207</td>
</tr>
<tr>
<td>Prognos*</td>
<td>Table 10</td>
</tr>
<tr>
<td>Real Life Data SLU</td>
<td>403</td>
</tr>
<tr>
<td>RTI Health Solutions*</td>
<td>507</td>
</tr>
<tr>
<td>Rutgers University</td>
<td>Table 4</td>
</tr>
<tr>
<td>RWS Life Sciences</td>
<td>909</td>
</tr>
<tr>
<td>Scientist.com</td>
<td>302</td>
</tr>
<tr>
<td>Self Care Catalysts</td>
<td>404</td>
</tr>
<tr>
<td>SHYFT Analytics</td>
<td>813</td>
</tr>
<tr>
<td>SIRIUS Market Access</td>
<td>1017</td>
</tr>
<tr>
<td>snapIoT</td>
<td>307</td>
</tr>
<tr>
<td>STATinMED Research</td>
<td>1000</td>
</tr>
<tr>
<td>SyneosMED Research</td>
<td>901</td>
</tr>
<tr>
<td>Taylor &amp; Francis</td>
<td>506</td>
</tr>
<tr>
<td>The American Journal of Managed Care</td>
<td>819</td>
</tr>
<tr>
<td>TransPerfect</td>
<td>806</td>
</tr>
<tr>
<td>TreeAge Software</td>
<td>916</td>
</tr>
<tr>
<td>TriNetX*</td>
<td>601</td>
</tr>
<tr>
<td>Tufts Medical Center</td>
<td>918</td>
</tr>
<tr>
<td>Universite de Bordeaux</td>
<td>802</td>
</tr>
<tr>
<td>University of Maryland – Pharmaceutical Health Services Research Graduate Program</td>
<td>Table 1</td>
</tr>
<tr>
<td>Veradigm*</td>
<td>805</td>
</tr>
<tr>
<td>Verantos, Inc</td>
<td>Table 3</td>
</tr>
<tr>
<td>Vitacess Limited</td>
<td>1008</td>
</tr>
<tr>
<td>Worldwide Clinical Trials</td>
<td>707</td>
</tr>
<tr>
<td>Xavier University</td>
<td>Table 2</td>
</tr>
<tr>
<td>Xcenda</td>
<td>501</td>
</tr>
<tr>
<td>YPrime</td>
<td>312</td>
</tr>
<tr>
<td>ZS</td>
<td>607</td>
</tr>
</tbody>
</table>

*Sponsoring Organizations*
Interested in exhibiting or sponsoring at a future ISPOR conference?
Contact sponsor@ispor.org
The ISPOR Science and Service Awards Program is designed to foster and recognize excellence and outstanding technical achievement in health economics and outcomes research (HEOR). ISPOR also awards lifetime achievement and leadership awards to those who advance these disciplines in the field and by service to the Society.

**Featured Award Recipients**

**2019 ISPOR AVEDIS DONABEDIAN OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARDEE**
Marc L. Berger, MD, Consultant, New York, NY, USA

**2019 ISPOR MARILYN DIX SMITH LEADERSHIP AWARDEE**
Josephine Mauskopf, PhD, RTI Health Solutions, Research Triangle Park, NC, USA

**Additional 2019 ISPOR Scientific Achievement Awards**

**Bernie J. O’Brien New Investigator Award**
Zirui Song, MD, PhD, Harvard Medical School, Boston, MA, USA

**Value in Health Paper of The Year Award**
Mónica Hérnandez, MSc, PhD, University of Sheffield, Sheffield, UK

**Value in Health Regional Issues Excellent Article Awards**
José Miguel Uribe-Restrepo, MD, MPH, Javeriana University Medical School, Bogatá, Colombia
Alexandra Beletsi, PharmD, PhD, Servier Hellas Pharmaceuticals EPE, Athens, Greece

**Award for Excellence in Methodology in Health Economics and Outcomes Research**
A. James O’Malley, MS, PhD, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA

**Award for Excellence in Application of Health Economics and Outcomes Research**
William V. Padula, PhD, MS, University of Southern California, Los Angeles, CA, USA

Awardees are being honored at the ISPOR Inaugural Awards Banquet on Sunday, May 19, 2019.
2019 ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award

ISPOR’s most prestigious award, the Avedis Donabedian Outcomes Research Lifetime Achievement Award, was established to honor the body of work and contributions to the field made by the late Avedis Donabedian, MD, MPH. The Award recognizes an individual’s outstanding, life-long achievement in improving health outcomes.

2019 ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Awardee

Marc L. Berger, MD, Consultant, New York, NY, USA

Marc L. Berger, MD, is a semi-retired, part-time consultant. Until July 2017, he was vice president, Real World Data and Analytics at Pfizer, Inc. Marc has held senior-level positions in industry including executive vice president and senior scientist at OptumInsight; vice president, Global Health Outcomes at Eli Lilly and Company; and vice president, Outcomes Research and Management at Merck & Co., Inc. He currently serves as advisor to several companies, including SHYFT Analytics. Additionally, Marc contributes to ongoing efforts by ISPOR and the Duke-Margolis Center for Health Policy to recommend how real-world evidence can be produced to enhance and expand its usefulness for regulatory agencies and other healthcare authorities. Marc has written or cowritten more than 130 peer-reviewed articles, book chapters, and other publications on a range of topics, including health services research, outcomes research, health economics, and health policy.

2019 ISPOR Marilyn Dix Smith Leadership Award

The Marilyn Dix Smith Leadership Award was established in 2014 in honor of ISPOR’s Founding Executive Director, Marilyn Dix Smith, RPh, PhD. The Award recognizes one individual each year that has provided extraordinary leadership to the Society.

2019 ISPOR Marilyn Dix Smith Leadership Awardee

Josephine Mauskopf, PhD, RTI Health Solutions, Research Triangle Park, NC, USA

Josephine Mauskopf, PhD, is vice president of Health Economics at RTI Health Solutions. She has over 30 years of experience both as a consultant and within the pharmaceutical industry designing and implementing health economic research strategies for prevention and treatment of infectious diseases, psychiatric illness, and neurologic diseases. She has been an active member of ISPOR since its beginning. She has presented posters, podiums, workshops, and issues panels regularly at the international and European conferences. She served as editor-in-chief for Value in Health from 2002 to 2010. She cochaired 3 ISPOR task forces: 2 for budget impact analysis and 1 for economic evaluation of vaccination programs and served on the CHEERS Task Force. The Budget Impact Analysis Task Force Report and related publications have served as the basis for country-specific guidelines. With other ISPOR members, she developed and presented a premeeting course on budget impact analysis that has trained many ISPOR attendees. She served on the ISPOR Board of Directors from 2014 to 2016.
Optimizing patient access with evidence of product value, effectiveness & safety

Real-World Evidence
Patient-Centered Research
Evidence Synthesis, Modeling & Communication
Market Access
Interventional Studies
Pragmatic Studies
Medical Writing

JOIN OUR TEAM. MAKE YOUR WORK MATTER.

We are growing rapidly and looking to expand our team with people who want to make a difference, grow their careers, and work in a collaborative environment with some of the best in the industry.

We are actively recruiting for positions in all areas.

Visit evidera.com/careers to view all open positions.

evidera.com
CHEORS
COMPLETE HEOR SOLUTIONS

For All Your HEOR Needs Round-the-Clock!

Economic Modeling  |  Real World Large Data Studies  |  Dossier  |  Medical Writing

Over 150 HTA Submissions Completed
cross 40 countries Worldwide
in just 4 years!

Why Choose CHEORS?
- Senior team each with 15-25 years of in-house pharmaceutical industry experience
- Highly technical staff leads every project
- Flexibility to put larger teams to deliver on tight timelines

Our unique database analysis solution allowed one client to complete more than 25 studies in less than a year

Contact us to Learn More!
We have offices in Canada, U.S., and Asia and we can be reached at:
  Michael Marentette: michael.marentette@cheors.com
  Bridget Corbett: bridget.corbett@cheors.com

We are hiring, please visit our booth!
HOW CAN WE SOLVE HEALTH CARE PROBLEMS BEFORE THEY EVEN ARISE?

WE KNOW HOW. WE ARE THE HOW.

*Visit us at booth 815* during ISPOR 2019 in New Orleans.
Reframe the debate on the value of your healthcare innovation

Precision is in New Orleans and ready to troubleshoot your challenges—schedule a complimentary 15-minute consultation with some of the most well-regarded experts in the field today.

To schedule your 15-minute time slot with an expert, stop by Booth 611 during ISPOR or email us at: info@precisionhealtheconomics.com

Three of the Precision experts in attendance:

Anupam Jena, MD, PhD
Scientific Advisor,
Associate Professor of Health Policy,
Harvard Medical School

Jeroen Jansen, PhD
Chief Scientist

Ross Maclean, MD, PhD, MBA
Executive Vice President,
General Manager
Global reach.

Local expertise.

When your market access needs take you anywhere and everywhere . . . partner with Xcenda.

Our integrated research environment is more robust now than ever before. We’ve added new and growing streams of integrated clinical data and large volumes of directly accessible, integrated clinical oncology data for deeper insights for your entire product life cycle – from clinical development through real-world evidence. We take pride in providing you a holistic view and delivering scientific expertise, user experience, and clinical outcomes to support you wherever you are in your journey.

Visit booth 401 at ISPOR in New Orleans.
Big data.
Bigger analytics.

Combine world-class big data, analytics and AI to increase efficiency in your research and accelerate time to value.

Visit us at Booth #911

© Copyright IBM Corporation 2019. IBM, the IBM logo and ibm.com are trademarks of IBM Corporation in the United States, other countries or both. Other product and service names might be trademarks of IBM or other companies.

Together we improve outcomes.

ICON’s Commercialisation & Outcomes experts deliver integrated solutions to identify, generate, synthesise and communicate the outcomes evidence that regulators, payers, providers and patients need to make informed health decisions.

ICON and You. Partners making a difference.

ICONplc.com/commercialisation
Real world data and advanced technologies are shortening timelines, improving the impact of research investments, and helping therapies reach patients faster. Use external comparators to accelerate clinical development. Use evidence platforms for on-demand analytics. The possibilities are exciting.

Others may offer a way forward. IQVIA gives you a way further.

---

CLARITIS™

THE LINK BETWEEN DATA AND EVIDENCE.

For the first time ever, companies are able to uncover previously unseen insights about the patient by linking of Patient Reported Outcomes and Clinical Data together using Kantar’s Claritis solution.

Visit us at Booth #900 to learn more from our experts about this new linked data solution.

www.kantarhealth.com
HEOR RESOURCES Comprehensive Tools. Comprehensive Knowledge.

ISPOR members, through its working groups, have developed a rich repository of HEOR resources that set the standard for research excellence in the field. Interest in the field of health economics and outcomes research (HEOR) has grown exponentially as governments and other payers grapple with how to provide the best possible health outcomes at affordable costs. At ISPOR, we believe that every healthcare decision should be informed by the best scientific research derived from rigorous, proven methodologies. Toward that goal, the Society’s mission is to promote HEOR excellence to improve decision making for health globally.

- Good Practices for Outcomes Research
- Pharmacoeconomic Guidelines Around the World
- Global Healthcare Systems Road Maps
- Scientific Presentations Database
- International Digest of Databases
- Assessing the Evidence for Decision Makers
- Outcomes Research Guidelines Index
- Health Technology Assessment Central

www.ispor.org
1. **Drug Spending and Pricing**
   This subject has expanded beyond the pricing of pharmaceuticals to encompass drug spending and its impact on payers’ healthcare budgets.

2. **Going Beyond Universal Health Coverage**
   Universal healthcare cannot be universal without ensuring that patients do not face undue barriers to accessing healthcare.

3. **Real-World Evidence**
   There is increasing interest and potential for converting real-world data into real-world evidence to inform healthcare decision making.

4. **Aging Population**
   Elder care and long-term care will continue to be global healthcare challenges as the number of people in the world aged 60 years or older continues to grow.

5. **Price Transparency: Not Just About Drugs**
   The lack of transparency in the pricing of healthcare services impedes consumers’ healthcare decision making.

6. **“Big Data” Continue to Make Noise**
   The use of “big data” can assist clinicians in making better healthcare decisions for their patients.

7. **Value Assessment Frameworks**
   Value assessment frameworks can be an important element in moving towards a more value-based care model.

8. **Healthcare Decision Making in Low-Income Countries**
   The difference between health technology assessment use by high-income and low-income countries is notable.

9. **Personalized/Precision Medicine**
   As researchers continue to determine the roles that genes play in diseases, HEOR will be needed to evaluate the diagnostics and drugs derived from their discoveries.

10. **Unhealthy Behaviors**
    The root causes of many chronic diseases include a host of unhealthy behaviors that lead to a variety of diseases responsible for the majority of all deaths worldwide.

© 2019 ISPOR – The professional society for health economics and outcomes research
Key Information

**WI-FI, INTERNET AND CONFERENCE APP ACCESS**

**Network:** ISPOR2019  Password: HEALTHCORE

Wi-Fi is available in the convention center. Wi-Fi is only intended for checking email and using the conference mobile app, not for downloading files. Connection speeds will vary depending on the volume of users. Download the mobile app on your smartphone or tablet:

- [ISPOR Meetings](#)
- [Google play](#)
- [App Store](#)

Can't download the app? Use your web browser: https://my/ISPOR2019.zerista.com/

Use the same details as used for the my/ISPOR2019 web pages. Your ISPOR conference app account email address is the same email address used for your conference registration.

Need help? Select "Need help logging in?" on the login screen.

Wi-Fi Sponsored by HealthCare, Inc.

---

**REGISTRATION DISCLAIMER**

For security purposes all individuals must be registered and wear the official ISPOR Conference Name Badge to gain access to the conference, the sessions, the exhibit poster hall, and any other ISPOR activity. Onsite staff and security will monitor for name badges and will deny access if an individual does not have an official ISPOR Conference Name Badge. Individuals not wearing a name badge will be directed to registration.

Please be advised that if you lose your name badge and need to have it reprinted you cannot print that at the self-serve station; you will need to visit the registration help desk.

Because of the professional nature of the program, and safety and liability reasons, guests and anyone under the age of 18 are not permitted access to or to register for the conference. This includes access to the conference in general, to scientific presentations, and to the poster and exhibit hall.

---

**LANGUAGE INFORMATION**

All sessions at ISPOR 2019 are presented in English. ISPOR regrets that due to the disruption to other delegates, whisper translation (chuchotage) is not permitted in any session, including short courses. To discuss options to meet educational needs in multiple languages, please contact conferences@ispor.org.

---

**COAT CHECK**

You may check your coat, baggage, and/or poster with an attendant in the Coat Check Room, located in the lobby of Hall H of the convention center. Daily coat check fees are as follows: $2.00 per coat and $3.00 per bag/poster case. Cash and credit cards will be accepted.

---

**PRESENTATION SLIDES/POSTERS**

Plenary session, issue panel, workshop, ISPOR forum, and symposia slides will be available via the conference app and at the ISPOR 2019 Released Presentations page at www.ispor.org during/after the conference, subject to speaker approval. Podium and poster presentation abstracts and released slides or poster PDFs are available at the ISPOR Scientific Presentations Database (a searchable database of over 45,000 research papers presented at ISPOR conferences) at http://www.ispor.org/research_study_digest/index.asp

The Released Presentations page will feature many of the conference's slide presentations as PDFs. In 2018, more than 80% of the presentations were available to the public during/after the conference. The Released Presentations page is accessible via the conference mobile app and at www.ispor.org/ISPOR2019-Released-Presentations.

---

**SPEAKER INFORMATION**

Upload the final version of your slide presentation in the Speaker Ready Room on the SAME day of your session!

All speakers are encouraged to use the Speaker Ready Room to preview their slide presentations and/or upload an updated version. Presentations submitted to ISPOR Speaker's Corner by the specified advance deadline and all presentations uploaded/uploaded in the Speaker Ready Room 30 minutes prior to the session will be preloaded to the computer in the session room. All speakers are requested to arrive at their presentation room 15 minutes prior to the session start time. ISPOR staff will be available in the session room to assist the presenter.

A Speaker Ready Room is provided in Room 277 with the following opening hours:

- **Sunday, May 19**
  - 12:00PM - 6:00PM
- **Monday, May 20**
  - 8:00AM - 6:00PM
- **Tuesday, May 21**
  - 8:00AM - 6:00PM
- **Wednesday, May 22**
  - 8:00AM - 2:00PM

---

**ISPOR RESEARCH PRESENTATION AWARDS**

Awards are given for the best research presentations for podiums and posters in the categories of GENERAL, NEW INVESTIGATOR, and STUDENT (up to 3 in each category). All research podium presentations are considered for an award. The top 10% of research poster presentations, based on abstract review score, are considered for a poster presentation award. These are identified with a rosette and will be judged during the conference. Award recipients will be notified by email and recognized on the ISPOR website at the conclusion of the conference.

---

**SOCIAL MEDIA**

Communicating by way of social media is encouraged if it falls within embargo and communications rules.

**Be part of the live discussion**

- Tweet your comments to @ISPORorg during the conference using #ISPORAnnual
- Access expert insights and share your views on conference sessions at the ISPOR LinkedIn Discussion Group: http://bit.ly/ISPOR-LIn-Discussion
- Network with your peers on the ISPOR Facebook page: http://bit.ly/ISPOR-FB

---

**RECORDING & PRESS INFORMATION**

ISPOR supports the promotion of research presented at ISPOR conferences, while safeguarding sensitive information, data, and research findings that are not yet available to the public. Due to the sensitive nature of data, particularly preliminary unpublished research findings, all filming and recording of scientific sessions and the poster hall is prohibited during the conference, without the express written consent of ISPOR.

 Portions of ISPOR 2019 may be recorded by ISPOR. By participating in the discussions, conference registrants agree that ISPOR may electronically copy, videotape, or audio-tape their attendance at and involvement in any program. Registration and attendance at ISPOR 2019 constitutes an agreement by the registrant to ISPOR's use and distribution (both now and in the future) of their image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities. ISPOR will strictly enforce its rights as the exclusive licensee of all publication and reproduction rights to each presentation, and no presentation, in whole or in part, may be reproduced without approval from ISPOR.

 Conference attendees must gain approval from a speaker or poster presenter prior to quoting or publishing that individual's scientific results. Members of the press must identify themselves as such before questioning speakers and congress attendees if using the information in a professional capacity.

More detailed information on ISPOR's Press Pass, Legal, and Embargo Policies are available on ISPOR's News & Press page at the ISPOR website (www.ispor.org).

For further questions on these policies, please contact: Betsy Lane (blane@ispor.org), Director and Chief Marketing & Communications Officer.

---

**CONFERENCE PROGRAM DISCLAIMER**

Please be advised that while the conference program is designed to provide accurate information regarding the subject matter covered, the views, opinions, and recommendations expressed are those of the authors and speakers, not of ISPOR, and thus ISPOR does not guarantee the accuracy of the information disseminated. If professional advice is desired, please consult a competent professional.

---

**ANTITRUST COMPLIANCE**

It is the undeviating policy of ISPOR to comply strictly with the letter and spirit of all local and U.S. Federal, State, and applicable international trade regulations and antitrust laws. Any activities of ISPOR or ISPOR-related actions of its officers, Executive Committee Members, or members that violate these regulations and laws are detrimental to the interests of ISPOR and are unequivocally contrary to ISPOR policy.

---

**FINANCIAL DISCLOSURE INFORMATION**

Research podium and poster presentation financial disclosure information will be available online only at: https://www.ispor.org/valueinhealth/index.asp in Value in Health (Volume 22, Suppl 1) in June 2019. Faculty and staff involved in the planning or presentation of this conference are required to disclose all real or apparent commercial financial affiliations related to conference content. This information is available on request at the ISPOR Registration desk.

---

**QUESTIONS & INFORMATION**

Please ask ISPOR staff members for any additional information about the conference or about ISPOR. ISPOR staff can be identified by their ISPOR name badges.
Conference Rooms Floor Plans

THIRD FLOOR

SECOND FLOOR

Please enter the New Orleans Theater from the Mid-Level, one level above the Second Floor.

FIRST FLOOR

Network: ISPOR2019
Wi-Fi Password: HEALTHCORE

#ISPORAnnual

www.ispor.org
Systematic literature reviews are an essential component for obtaining data inputs or assessing the impact of health technologies on clinical, economic, or health-related quality of life. Systematic reviews may inform coverage decisions for drugs, devices, or public health interventions, and frequently are used in comprehensive health technology assessments. When conducted properly, systematic literature reviews pool all relevant data to allow a more efficient process for assessing value. Therefore, a full understanding of systematic reviews—and how to implement them in practice—is imperative for anyone involved in healthcare research, practice, and policy.

Recognizing the inherent usefulness of these types of studies, the Editors of *Value in Health* are issuing an open Call for Papers for systematic literature reviews on a wide array of topics that seek to inform healthcare decision making. Submissions do not need to focus solely on reviews of randomized controlled trials; they can include reviews of observational studies, economic evaluations, outcomes research studies, and preference-based assessments. Reviews can address any aspect of value in health (e.g., quality of life, resource use, and cost-effectiveness), but papers reporting reviews of studies containing only clinical endpoints are out of scope for this call.

Topics of interest include, but are not limited to:

- Systematic reviews of the value of drugs, devices, procedures, and other health technologies
- Evaluations that provide credible evidence of heterogeneity of treatment effects across comparator health interventions
- Systematic reviews of healthcare policies or the use of methods to assist policy making (e.g., MCDA)
- Methodological articles that address bias or other techniques to produce comprehensive assessments

Submissions received before **November 15, 2019** will have the best chance of being published in *Value in Health* in 2020. Final decisions regarding ultimate acceptance rest solely with the Editors.

Authors should submit manuscripts through the journal’s online submission system at [https://mc.manuscriptcentral.com/valueinhealth](https://mc.manuscriptcentral.com/valueinhealth) and be sure to classify their submissions as Systematic Literature Reviews.